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Summary
Corynebacterium Parvum is an anaerobic diphtherioid 
bacterium which suppresses the rate of development and 
spread of a wide variety of transplantable rodent tumours. 
It has also been suggested that the bacterium might be of 
therapeutic benefit to humans suffering from cancer. The 
experimental work of this thesis discusses some of the 
effects of C. Parvum on mononuclear phagocyte cells both 
in normal rats, and rats bearing carcinogen induced 
cancers of the colon. Particular attention has been paid 
to this class of cells since it is considered that they 
are the mediators of the anti tumour effects of the 
bacterium. In addition, the results of two clinical 
trials reporting the results of C. Parvum in the treatment 
of post operative human cancers are presented.
Experimental Work
The dose of C. Parvum used in the experimental work was 
calculated from preliminary experiments. C. Parvum was 
given to adult female Wistar Rats by a variety of routes 
at different dose rates. Stimulation of the 
reticuloendothelial system was assessed by measurements 
of the resulting splenomegaly. It was considered that 
the optimum dose calculated by this work would also cause 
stimulation of mononuclear phagocytes.
An experimental rat model has been described at the Sir 
William Dunn School of Pathology in Oxford which enables 
the continuous collection of effluent gut lymph containing 
mononuclear phagocytes. It is argued that these cells 
represent tissue mononuclear phagocytes and lymph 
collected in this way enables a dynamic assessment of 
cell traffic in the gut wall.
A dose of C. Parvum which caused marked reticuloendothelial 
stimulation had no measured effect on these gut associated 
mononuclear cells nor on cells showing the capacity to 
ingest antibody coated sheep red blood cells. These 
studies were repeated in rats bearing small colonic 
cancers induced by dimethylhydrazine. Once again the dose 
of C. Parvum which was given had no effect on gut 
associated mononuclear cells or phagocytes. However, the 
numbers of phagocytic cells were markedly suppressed in 
all of the tumour bearing rats, whether or not they had 
been treated with C. Parvum.
Since the dose of C. Parvum caused splenomegaly but had no 
effects on mononuclear phagocytes in effluent gut lymph, 
other effects of this treatment were studied.
The dose of C. Parvum which was used caused:
1. Blood changes : an immediate lymphocytopaenia with 
a concomittant granulocytosis in peripheral blood. 
Subsequently the granulocyte level returned to normal levels 
but the lymphocytes showed a small, but significant increase 
above the original value by two weeks after treatment. 
Monocyte numbers in the peripheral blood were not affected.
2. Peritoneal exudates and splenic macerates : esterase 
positive and phagocytic cells obtained from both of these 
sources showed a fall one week after treatment followed 
by a rise by two weeks.
3. Histological changes ; there was a marked increase in 
the area of the white pulp, and probably also the red pulp 
of the spleen. Both the spleen and caecal lymph nodes 
showed histological evidence of stimulation of the 
reticuloendothelial system. It had been hoped to identify
tissue macrophages using acid phosphatase, p glucuronidase 
and non specific esterase staining techniques. However, 
it was not possible to assess post treatment changes by 
this method.
Clinical
Two clinical trials are reported describing the use of 
C. Parvum in the adjuvant treatment of two common human 
cancers. In the first of these, the bacterium was given 
in a small intradermal dose along with an inoculum of 
autologous irradiated tumour cells to post operative 
patients after resection of Stage 1 and 2 lung cancer.
In this trial an attempt was made to stimulate specific 
immunity against residual tumour cells. In the second 
trial C. Parvum was given by serial intravenous injections 
to patients who had undergone resection of Dukes stage B 
& C colorectal cancers. This approach attempted to non 
specifically stimulate the reticuloendothelial system 
with the aim of increasing the destruction of residual 
tumour cells by "activated" mononuclear phagocytes.
In each trial nearly 100 patients were included with an 
equal distribution between the treatment and the control 
groups. It was apparent that the median times to recurrence 
or death were not influenced by the treatment in either 
trial.
Considerable enthusiasm for the use of bacteria in the 
treatment of human cancers was generated in the early 
1970's. This followed reports of improved remission rates 
notably after the use of B.C.G. in the treatment of 
acute lymphoblastic leukaemia and malignant melanoma.
Carefully constructed clinical trials have failed to 
support the continued use of this kind of treatment. 
Both the experimental and clinical work described in 
this thesis suggest that immune stimulation mediated • 
by bacteria will not provide an easy answer to the 
treatment of human malignant disease.
Aims of the study
Corynebacterium Parvum (C. Parvum) has been shown to 
stimulate the reticuloendothelial system and to suppress 
the growth of a variety of tumours in experimental animals. 
Reports of benefit from the systemic use of the bacterium 
in patients suffering from advanced cancer encouraged 
clinical trials. For example two such trials have been 
carried out in the Oxford Region, on patients who have 
undergone surgical excision of lung and colon cancers.
C . Parvum given systemically has an anti-tumour action 
which is considered to be mediated by cells of the 
mononuclear phagocyte system. (M.P.S.) This theory has been 
studied in normal rats and in rats bearing 
dimethylhydrazine induced colonic cancers.
Experimental Work
1. The principal aim of the study has been to
assess whether systemic C. Parvum influences 
M.P.S. cells in effluent gut lymph. These cells 
may reflect the state of M.P.S. cells within 
the gut wall. This study has been performed 
on both normal'rats and rats bearing 
dimethylhydrazine induced colonic cancers.
2. The effect of C. Parvum on M.P.S. cells 
in the blood, peritoneal exudates, the 
spleen and in tissue sections has been 
assessed.
3. As a preliminary to this work, a safe dose 
of the bacterium which reliably stimulates
the reticuloendothelial system was established.
Clinical Trials with C. Parvum 
Two clinical trials are reported.
1. Lung Cancert Lung cancer patients who had 
undergone surgical clearance of Stage I and II 
disease were randomised in the operating 
theatre to treatment or no treatment groups.
In those patients drawing treatment a tumour 
cell suspension was prepared and frozen. During
7
convalescence 2 x 10 of these cells were 
irradiated with 10000 rads and injected 
intradermally in the thigh along with 50 pig of 
C . Parvum.
2. Colorectal Cancer: Selected patients who had 
undergone surgical clearance of Dukes B & C 
colorectal cancer were randomised to treatment or 
no treatment groups. Patients drawing treatment 
commenced a series of intravenous infusions of
C. Parvum within 30 days of surgery after giving 
informed consent.
The capacity of C. Parvum to stimulate the 
reticuloendothelial system._______________
The ability of a large group of myobacteriae and 
propionibacteriae to stimulate the reticuloendothelial 
system (RES) has been widely investigated. (1) C. Parvum 
is one of a group of anaerobic bacteria which are members 
of the propionibacterium class. An "activated" RES, 
capable of increased tumour cell destruction could be of 
therapeutic benefit.
The clinical hope has been to use C. Parvum as a treatment 
to stimulate the host's anti-tumour defences but it 
seems important to survey the evidence that a real 
stimulation of the RES has taken place.
Bacteriology
C. Parvum is one of a large group of preferential 
anaerobic bacteria (some 500 being described by Prevot) 
which appear to quickly lose their pathogenicity on 
being cultured. Some of these bacteria can produce a 
fatal malignant disease of the RES both in experimental 
animal models and in humans. (1) In the animal models 
their injection causes lethal stimulation of the RES with 
the liver, lung, spleen and kidney showing increased 
numbers of histiocytes, lymphocytes and macrophages.
Prevot has a theory that recurrent anaerobic corynebacterial 
septicaemias occur in humans and eventually lead to the 
development of a malignant reticulosis. He also describes 
corynebacteriae being found in lymph nodes of patients 
with Whipples disease and claims that this is another
manifestation of over stimulation of the lymphatic 
system.
The increase in phagocytes caused by C. Parvum is 
paralleled by an increase in splenic and liver mass.
The most obvious result from the systemic use of 
C . Parvum is very marked hepatosplenomegaly and this 
forms the starting point for examining RES stimulation.
1. Hepatosplenomegaly; The observed increase in 
weight of liver and spleen after C. Parvum in experimental 
animals is dose related (2 & 3) and peaks about two 
weeks after the injection. This increase is only noted 
after inoculation which enables the bacterium to gain 
systemic exposure, that is, by the intravenous or 
intraperitoneal routes. After subcutaneous or intradermal 
inoculation local lymph nodes undergo hypertrophy but 
no systemic organomegaly occurs. That the enlargement 
of the liver is associated with an increased clearance of 
foreign particles by phagocytosis was shown in the 
classical work of Halpern. (2) He also showed that the 
increased rate of clearance of colloidal carbon was dose 
related. Histological sections of livers from these animals 
showed increased numbers of carbon containing phagocytes 
and lympho-histiocytic granulomata. The spleen showed 
marked hyperplasia of both the red and white pulps, an increase 
in histiocytes and lymphocytes, but carbon containing 
macrophages were limited to the red pulp. These appearances 
reverted back to normal a few weeks after injection of 
C. Parvum. C. Parvum induced organomegaly depends on 
direct interaction between the bacterium and the organ 
concerned (4) and is also partly dependent on lymphocyte 
trapping. (5)
Experiments using radiolabelled C. Parvum show that 
it becomes distributed principally in the spleen, liver 
and lungs. Smaller amounts are initially found in 
the blood, kidney, thymus and bone marrow but disappear 
rapidly. These observations remain the same with a 
variety of radiolabels. (6, 7 & 8) Autoradiographic 
and fluorescence studies show that the C. Parvum is 
localised within mononuclear cells. (8)
2. Phagocytosis and Fc receptor bearing cells of
cellular homogenates (9): The work in this field appears 
to have been limited to an analysis of the macrophage 
content of tumour preparations. A spontaneously arising 
mouse mammary adenocarcinoma was transplanted syngeneically. 
Systemic C . Parvum caused marked splenomegaly and partly 
inhibited tumour growth. There was no increase in Fc 
receptor bearing cells nor of carbon ingesting cells 
within the tumour. A relative increase in the proportion 
of Fc receptor bearing cells over phagocytes was observed.
It was suggested that this is due to the presence of 
increased numbers of non phagocytic monocytes which may 
represent the effector cell population. (9) C. Parvum
has been observed to exert an appreciable anti-tumour 
effect without influencing Fc receptor cell concentration 
in a transplantable methyl cholanthrene induced mouse 
fibrosarcoma. (9, 10 & 11)
3. Phagocytosis of Radiolabelled particles : Radio­
active emissions from various tissues some time after the 
intravenous (I.V.) inoculation of radiolabelled red 
blood cells has been studied in rats. This enables an 
estimate of the phagocytic capacity of each tissue to be 
made. (12)
The radioactive emission rate from the liver was 
considerably increased after C. Parvum. Although 
the spleen showed little such increase in the early 
stages there was an increase by day ten post C. Parvum.
The emission rate correlated well with the disappearance 
of injected colloidal carbon from the blood, hitherto 
the standard _in vivo test for assessing stimulation of 
phagocytosis. By calculating the organ emission rate/ 
blood emission rate a figure is obtained for the uptake 
ratio. In this study the splenic uptake ratio exceeded 
that of the liver by day ten after C. Parvum.
4. thymidine uptake; Experiments involving the
tritiated thymidine uptake of liver cells in sublethally 
irradiated rats showed that C. Parvum not only induces 
an influx of new sinusoid lining (Kupffer) cells from an 
extra hepatic source, but also stimulated proliferation 
of the pre-existing cell population. (13)
5. Analysis of tissue and serum enzyme concentrations; 
Cellular suspensions obtained from chickens both by 
tracheal lavage and whole lung homogenisation were analysed. 
It was found that after intravenous C. Parvum the 
suspensions contained an increase in acid phosphataseJB -
D - glucuronidase, ^ D galactosidase and phospholipase A. 
This increase was due both to greater numbers of cells 
containing the enzyme and also to an increase ih enzyme 
concentration per cell. (14)
The incubation of macrophages with anaerobic 
corynebacteriae for an hour caused a great increase 
in the concentration of acid phosphatase, JB - D 
glucuronidase and ^ - D galactosidase found after lysis 
of these cells. A high percentage of these enzymes were 
also found free in the supernatant.
In addition to analysing the concentration of these 
hydrolases in the acute phase their levels were measured 
in tissue macrophages at various time intervals up to 
three weeks after TV and intraperitoneal (IP) injection 
of various anaerobic coryneforms. (15) This work showed 
that the enzyme content per cell gradually increases. It 
was suggested that C. Parvum both stimulates synthesis of 
new enzyme and also the release of pre-formed enzymes.
This would explain the increased measurements found in both 
the acute and chronic groups.
Wilkinson suggests that the anaerobic coryneforms have cell 
wall molecules with an affinity for macrophage microfilaments 
and which stimulate the discharge of lysozomal enzymes.
A subsequent period of protein synthesis and division 
ensures the appearance of a population of stimulated 
macrophages containing high enzyme concentrations. (16)
Increased levels of serum lysozyme were found in mice being 
treated with C. Parvum. These animals harboured 
isotransplanted methyl cholanthrene induced fibrosarcomas 
or spontaneous mammary carcinomas. The increased lysozyme 
levels were not found to be of any value as prognostic, 
indicators. (17)
A chemotactic factor has been observed in both cultures 
and culture filtrates from many strains of anaerobic 
coryneforms. (18) This factor has been shown to be
strongly and specifically attractive to monocytes and 
may be responsible for the migration of monocytes into 
areas of C. Parvum localisation vivo.
6. Stimulation of the Bone Marrow: The promonocyte
precursors of all cells of the mononuclear phagocyte 
system (MPS) are found within the bone marrow. Marrow 
cell suspensions were obtained from the femoral shafts 
of experimental animals and then incubated with a source 
of colony stimulating factor for one week. Discrete 
colonies formed, each of which was taken to represent one 
original promonocyte. After C. Parvum there was a highly 
significant increase in the number of such colonies found, 
(19 & 20) It was also noted that strains of C. Parvum 
with the highest anti-tumour activity appeared to have the 
greatest effect in increasing the stimulation of macrophage 
progenitor cells. (21)
Summary
The evidence suggests that C. Parvum increases MPS cell 
numbers, their phagocytic capacity, their concentrations 
of acid hydrolase enzymes, and influences localisation of 
these cells.
Human Studies
Investigations have been much more limited in this field 
but some evidence exists to suggest that the effect of 
C. Parvum on the human MPS is the same as that in animals.
Patients with cancer being treated with C . Parvum showed
125an increased rate of clearance of I labelled 
aggregated albumin from the blood. This test was shown 
to closely parallel the disappearance of colloidal carbon 
in experimental animals and by inference confirms that 
C. Parvum increases the phagocytic activity within the 
RES of cancer patients. (22)
After intravenous C. Parvum a transient monocytopaenia 
has been observed. This has variously been described as 
lasting for 24 hours, four and five days and ten days.
(23, 24 & 25) It has been suggested that the monocytopaenia 
is due to the sequestration of blood monocytes within the 
RES. The subsequent monocytosis which appears at about 
14 days is thought to be due to bone marrow stimulation.
Conclusion
There is clear evidence that C. Parvum can stimulate the 
RES in animals and humans. Whether this stimulation can 
be harnessed to increase immunity is not yet clear. 
Clarification of the role of the MPS against spontaneously 
arising malignancy is needed. It seems unlikely that a 
single cell line will prove capable of attacking malignant 
tissues alone. Some form of co-operative response may 
exist and identification of participating cells is an 
urgent priority.
10
Immunotherapy
Ehrlich's original concept of an immune surveillance 
mechanism has been restated more recently by Burnet.
(26) According to this theory malignant transformation, 
rather than being a rare event, occurs frequently, but 
these cells are eliminated as they arise by a powerful 
immune mechanism. Clinically detectable cancer will 
only become apparent when this system is overwhelmed.
As a corollary it should be possible to stimulate these 
putative mechanisms increasing the resistance of the 
host to the development and spread of cancer.
Evidence implicating the immune system in the development 
and spread of cancer
It seems likely that the patients immune system is capable 
of mounting an attack against malignant cells and that 
these defences are broken down by advancing disease.
Malignant cells can be found in the general circulation 
during the growth of primary tumours. It is probable that 
these cells only rarely survive to develop into secondary 
deposits of cancer. (27) The factors which normally 
prevent this development are unknown. Local factors may 
play a part. For example, engulfment by cells of the 
mononuclear phagocyte system (MPS) in the same way as they 
would deal with invading bacteria is possible. Macrophage 
and lymphocyte activity at the periphery of tumours is 
reported to confer an improved prognosis (28) as does 
sinus hyperplasia in the draining lymph nodes. (29) These 
histological signs of activation of the MPS seem beneficial 
The opposite may be the case where activation does not, 
or cannot, occur.
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Patients bearing small localised tumours are usually 
immunologically competent as measured by skin tests of 
cellular immunity, serum immunoglobulins and- lymphocyte 
numbers. This is not the case in those who have advanced 
malignant disease, many of whom show suppression of 
cellular and humoral immunity. (30, 31, 32, 33, 34 & 35)
Cellular immunity can be clinically measured by the 
subcutaneous inoculation of a variety of skin test 
antigens. The substances inoculated usually include 
mumps virus, purified protein derivative of the tubercle 
bacillus, streptokinase, streptodornase, trichopyton and 
Candida albicans. Response is measured by the development 
of cutaneous nodules and patients showing no reaction are 
termed anergic. There is a clear relationship between 
suppression of these responses and prognosis, patients 
with the most suppressed responses having the poorest 
outlook. This is true for various solid tumours (30) acute 
leukaemia (35) and lung cancer. (34) It is also
recognised that patients undergoing therapeutic immune
suppression after transplant surgery have a high incidence 
of neoplasia, particularly lymphomas. (36)
Some oncogenic viruses induce tumours in normal neonatal 
animals, but will only do this in adults which have been 
immunosuppressed. Chemical carcinogens on the other hand, 
have an equal effect in inducing tumours in immune suppressed 
and normal animals. (27)
Reports that some malignancies undergo spontaneous regression 
may suggest alteration of the host/cancer relationship.
This phenomenon has been observed most commonly in malignant
melanoma. "Immune" sera from those fortunate patients can
be transferred with benefit to those suffering from the 
same disease. (37)
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More information is required to substantiate the view 
that immune surveillance is important in determining the 
incidence of malignant disease. Immune status may play 
a greater part in governing the growth pattern of 
tumours,
Transplanted tumours which do not normally metastasize 
can do so if grown in immune suppressed animals. It may 
be that these hosts, be they animal or human, are unable 
to eradicate residual tumours after surgery, chemotherapy 
or radiation treatment as these can all cause long lasting 
immunosuppression. (38, 39) Moreover these treatments 
may render the patients more likely to develop métastasés 
and supports the viewpoint that restoration of immune 
competence would be beneficial.
The antigenicity of tumours
In 1957 Prehn and Main succeeded in demonstrating tumour 
specific antigens. (T.S.A.'s) (40) Since then large,
numbers of T.S.A.'s have been identified in carcinogen 
induced animal tumours. The possibility that such antigens 
would be present in human tumours, enabling the development 
of specific immunotherapy led to a resurgence of interest 
in this approach. The original investigations were 
carried out on a murine methyl cholanthrene induced sarcoma 
and it remains far easier to demonstrate T.S.A.'s in 
carcinogen induced malignancy. It has not been possible 
to identify T.S.A.'s in human cancer. Human tumour 
associated antigens (T.A.A.'s) like carcinoembryonic 
antigen (C.E.A.) have however been identified. (41) 
Although originally thought to be associated only with 
cancer of the colon such specificity has now been disproved 
Serum C.E.A. levels are elevated in a variety of conditions,
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This was the first of a group of tumour associated 
antigens described in malignant disease. As a group 
they resemble antigens found in the developing foetus.
It is suggested that they are produced by malignant 
cells showing reversion to the less differentiated 
state found in the primitive cells of the developing 
foetus.
These are termed oncofoetal antigens and, although 
not absolutely specific for any given malignant condition 
they have proved to be useful in monitoring the progression 
of some cancers. The other oncofoetal antigen which is 
particularly important is OC foetoprotein. This is 
elevated in many cases of testicular teratoma and all 
cases of hepatocellular carcinoma. However, these 
antigens are not at present of widespread application in 
the management of cancer patients.
General approaches to immunotherapy
Passive
In passive immunotherapy, the effector arm of an immune 
response directed against tumour specific antigens is 
mediated by either antibodies or lymphoid cells produced 
in donors, usually animals. This approach was used as 
long ago as 1895 by Herecourt and Richet. (42) They 
raised antisera in dogs and donkeys by immunising the 
animals with fragments of the patients tumour. 50 patients 
were treated with the resulting antiserum. Diminution 
of tumour size, lessening of pain and improvement in 
general condition was claimed to result in many cases.
More recently 200 patients were treated with globulins 
from horses immunised with human tumours. Again subjective
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improvement was claimed to occur in a large number 
of patients with occasional objective evidence of 
benefit. (43)
Lymphoid cells can be prepared from an animal that has 
been immunised with tumour cells. These are then given 
to the original tumour bearing host. If the host is 
immunosuppressed a graft versus host reaction may ensue.
This may destroy as many normal host cells as tumour 
cells and would therefore not be useful. However, in the 
immunocompetent host the graft versus host reaction does 
not occur since the injected lymphocytes are unable to 
become established. This type of procedure is of limited 
application. In the region of 10^ cells require to be 
transferred and clinical benefit has not been demonstrated. 
(44)
Cell free extracts which contain RNA from immunoblasts 
raised against tumours in allogeneic or xenogeneic hosts 
exert an anti-tumour action. (45) While injection of 
these extracts may transfer specific immunity, it is 
difficult to obtain a large enough quantity to be clinically 
useful.
Immune macrophages from the peritoneal cavities of immunised 
mice can be used to control ascites, provided they are 
injected directly into the ascitic fluid. Monocytes may 
also be capable of transfer in this way and have the 
advantage of recirculating. However, it is difficult to 
obtain large enough quantities to evaluate clinical 
response. (46)
15
Lymphoid cell transfer has been used clinically in the 
management of malignant disease. Nadler and Moore 
reported cross immunisation of pairs of patients 
suffering from advanced malignancy (mainly melanoma). 
Exchange of peripheral blood lymphocytes was then 
carried out and a few regressions noted. (47)
Active Immunotherapy
Specific
AutO“immunisation with irradiated tumour cells leads to 
the transient appearance of antibodies specifically 
directed against the inoculated tumour. At the same time 
serum tumour antigen levels fall. It is argued that by 
altering the situation from antigen excess to antibody 
excess, circulating cytotoxic cells will be enabled to 
act against the malignant cells in the tumour since they 
will no longer be blocked by T.S.A.'s. (27) Whether 
this form of immunisation will also increase the level of 
circulating cytotoxic cells is unclear. To achieve 
increased antibody levels repeated inoculation with 
large numbers of cells is required.
This therapeutic approach was first reported in 1902. (48)
An autologous tumour cell suspension was used as a vaccine 
in patients suffering from advanced malignancy. No clear 
cut evidence of benefit resulted. A more recently 
reported series of 232 patients with advanced gynaecological 
cancer treated with autologous irradiated tumour extract 
similarly failed to show any evidence of benefit. (49)
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In an effort to enhance the immunogenicity of the 
inoculum various adjuvants have been given. Pertussis, 
typhoid A and B, and complete Freunds adjuvant have 
been used, (50) but again no clear evidence of benefit 
resulted.
Non Specific
Non specific immunotherapy aims to increase immunological 
reactivity usually by stimulation of the reticuloendothelial 
system. This has the effect of increasing cell mediated 
and humoral reactivity to a variety of unrelated antigens.
Bacille Calmette Guerin (B.C.G.) has been given regularly 
by dermal abrasion in the treatment of acute lymphoblastic 
leukaemia. Mathe's report, in 1969, that this treatment 
had significantly prolonged the length of remission of 
this disease, probably fired more optimism for immunotherapy 
than any other single report. (51, 52) His patients also 
received irradiated allogeneic leukaemic blast cells, 
routine anti leukaemic chemotherapy and in some cases other 
iramunostimulants, like Poly 1, Poly C and C. Parvum. It 
was therefore difficult to know exactly what contributed 
to the improved results.
C. Parvum is an even more potent stimulant of the RES than
B.C.G. Given systemically its anti-tumour action is 
likely to be non-specific and mediated by cells of the 
M.P.S.
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Bacteria in the treatment of cancer
Bacteria, bacterial extracts and parasites have been 
quite extensively studied in the treatment of cancer.
(53)
One of the first reports of benefit in cancer treatment 
was Coley's claim of tumour response to streptococcal 
endotoxin in 1906. (54) Patients suffering from
advanced cancer were inoculated with the endotoxin 
and developed fever as a result. Tumours were noted to 
become smaller with improvement in the general condition 
of the patient in a significant number of cases. These 
results and others from similar trials with bacterial 
endotoxins have been reviewed and their use is still 
advocated by Nauts. (55) Although there have been 
persistent suggestions of benefit from this treatment, 
critical analysis shows an absence of control patients 
and improvement has often been claimed on a purely 
subjective basis.
The effects of repeated treatment with B.C.G., usually 
given by scarification, have been extensively studied in 
patients suffering from malignant melanoma.
This approach, particularly when treatment is given 
directly into the shin lesion, sometimes leads to regression 
of both injected and non-injected shin nodules. However, 
there is no evidence that this has any effect on visceral 
métastasés, or the survival of the patient. In addition 
the treatment is painful and frequently causes local 
inflammatory reactions which may lead to dermal ulceration. 
This approach has been extensively evaluated in malignant 
melanoma, particularly by workers in the U.S.A. Reports
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that repeated intradermal B.C.G. either given alone 
or in combination with autologous irradiated melanoma 
cells led to a 50% reduction in métastasés and an 
improved remission rate, (55) prompted similar trials 
in this country. (57, 58) However, it rapidly became 
apparent that the treatment group of patients in this 
country, far from having improved results showed 
worrying evidence of early recurrence of disease and 
the trials were brought to an end.
Reference has already been made to Mathe's report of 
improved remission rates using‘B.C.G. in the treatment of 
acute lymphoblastic leukaemia. (51, 52) B.C.G. was 
added to the standard treatment of this condition in a 
large series carried out under the auspices of the 
Medical Research Council. (59) In their report no 
added benefit occurred in the B.C.G. treated group.
Both of these examples illustrate the complexity of the 
problem. While one group of workers claim improved 
results others find none, or even the suggestion of 
worsening of outlook.
While B.C.G. has been extensively tested, its side effects 
make it an unpleasant form of treatment. Cell wall 
extracts of B.C.G., for example, methanol extractable 
residue (MER) have been developed which may result in 
equally effective immune stimulation without causing the 
side effects. (60) The anaerobic diphtheriods have been 
shown to cause intense stimulation of the RES. C. Parvum 
and C. Granulosum have been investigated in the hope that 
this stimulation would boost anti tumour immunity.
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C . Parvum as an anti tumour agent 
Animal Studies
Since 1966 when first Woodruff in Edinburgh, then 
Halpern in Paris (61, 62) demonstrated that 
systemically administered C. Parvum exerted an action 
against experimental animal tumours its anti tumour 
effects have been repeatedly demonstrated. (63)
However, the bulk of this work has been carried out 
in syngeneically transplanted murine tumours. These 
are either induced with chemicals or oncogenic viruses. 
Those arising spontaneously have been maintained by 
passaging usually for several generations. These animal 
tumour models bear little similarity to the human 
situation, but such experiments may élucidé the 
mechanism by which C. Parvum exerts its anti tumour 
action. Improvement in understanding might reasonably 
be expected to clarify the naturally occurring host 
defence mechanisms against cancer.
Systemic Injection
Woodruff and Boak demonstrated that intravenous C. Parvum, 
given as a single injection 8 to 12 days after the 
subcutaneous implantation of a spontaneously arising 
mammary carcinoma, delayed the appearance and subsequent 
growth of the tumour. (61) Halpern then showed a 
similar suppression of growth of a transplanted sarcoma 
(Sarcoma J) if the bacterium was given within 2 days of 
tumour inoculation. His group also reported suppression 
of growth of the Ehrlichs ascites tumour when C. Parvum 
was given intraperitoneally at the same time as the tumour 
cells. (62)
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The Edinburgh group then found that not only was 
intraperitoneal C. Parvum effective in suppressing 
growth when given within 3 days of inoculation of the 
mammary adenocarcinoma, but that the same effect was 
noted in two unrelated methylcholanthrene induced 
sarcomata. Elucidation of the possible mechanism came 
when exactly the same anti-tumour effect was found in 
T cell deprived mice. (64)
Systemically administered C. Parvum limits the growth 
rate of some transplanted tumours but has a more marked 
effect against métastasés. For example the Lewis lung 
carcinoma is a transplantable tumour of mice, which 
after subcutaneous inoculation leads to a locally 
enlarging neoplasm and widespread lung métastasés. I.V.
C . Parvum given either at the time of challenge with 
the tumour inoculum or within 7 days caused suppression 
of growth of the primary tumour. If the C. Parvum was 
given by either the I.V. or I,P. routes 3 or 4 days prior 
to tumour cell challenge then a marked decrease in the 
subsequent development of métastasés resulted. Subcutaneous 
inoculation of C. Parvum had no effect. (55)
Using the same animal tumour model, the mice were submitted 
to prior thymectomy, whole body irradiation and marrow 
reconstitution to render them T cell deficient. This had 
no influence on the effect of C. Parvum against both primary 
and metastatic tumours. When the animals were given silica 
or cortisone, both macrophage toxins, a considerable 
increase in métastasés resulted. C. Parvum given after 
these toxins abrogated this effect, possibly by stimulating 
an increased formation of new M.P.S. cells in the bone 
marrow. (660 Another interesting observation made with 
this model was that non-specific operation (amputation of
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a limb) led to an increased number of métastasés and 
that C. Parvum given systemically abolished this 
effect. (56)
The closely related bacterium Corynebacterium 
Granulosum is effective against the development of 
pulmonary métastasés after the intravenous inoculation 
of a syngeneic fibrosarcoma in mice. The bacterium in 
this case was administered intraperitoneally and the 
maximum effect against the development of métastasés was 
only seen when inoculation was within 2 days of tumour 
cell challenge. (67)
Although systemic C. Parvum suppresses the development of 
métastasés in T cell depleted animals, anti lymphocyte 
serum (ALS) has been shown to prevent this action of the 
bacterium. (68) A.L.S. acts mainly by destroying long 
lived T^ lymphocytes. (69) The anti metastatic effect 
of C. Parvum while largely mediated by macrophages seems 
to require co-operation from these T^ lymphocytes.
Using transplantable tumours which cause ascites (Meth A 
ascitic, S37 ascitic and Ehrlichs ascitic), intraperitoneal 
C. Parvum was protective provided it was given prior to 
tumour transplant. However, in this model prior splenectomy, 
thymectomy or treatment with A.L.S. had no effect. (70)
C. Parvum also limits tumour growth in complement deficient 
animals. (71) The animals used were congenitally 
deficient in C5 and were challenged with both a 
spontaneously arising mammary carcinoma and a methyl­
cholanthrene induced sarcoma.
While repeated doses of C. Parvum stimulate an increased 
anti C. Parvum antibody titre this approach is no more
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effective than single doses in preventing the development 
of pulmonary métastasés in the Lewis lung cancer model.
(72) Indeed, when repeated inoculations of C. Parvum 
were given with a further dose in the day of tumour 
challenge, the anti-metastatic capacity was abrogated.
It is unclear whether the bacterium, when used in this 
way, stimulates suppressor cells, causes the appearance 
of circulating immune complexes blocking cell mediated 
immunity or simply produces a high titre of anti C. Parvum 
antibody which blocks its anti-metastatic effect. The 
observation does suggest that great caution should be 
taken when contemplating the clinical use of repeated 
C. Parvum.
Even in these animal studies systemically administered 
C . Parvum has not universally shown anti-tumour 
capabilities. (73) An investigation which closely 
paralleled those described on the Lewis lung cancer gave 
different results. Using two early generation transplantable 
adenocarcinomata which had arisen spontaneously and were 
of low immunogenicity, C. Parvum given I.P. four days 
prior to excision of the subcutaneously growing primary 
tumours had no effect on the subsequent development of 
lung métastasés. Further efforts to induce an anti-tumour 
action by the inoculation of irradiated tumour cells 
were also ineffective. The authors concluded that there 
was, "no evidence that bacteria can superimpose specific 
antigenicity on tumour cells." Over three quarters of 
the tumours being used in the laboratory study of C. Parvum 
vaccine have been artificially induced by chemicals, 
radiation or oncogenic viruses. Of the other quarter, i.e. 
those which have arisen spontaneously, all are more than 
20 years from their time of origin. For example the Lewis 
lung cancer arose more than 25 years ago and has been
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exchanged between many laboratories and passaged in 
hundreds of animals. The opportunity for the 
acquisition of artefactual immunogenicity is very high, 
for example by genetic diversification or viral 
contaminati on.
When C. Parvum was given repeatedly intraperitoneally 
during the induction of colonic cancers using dimethyl- 
hydrazine, (DMH) rather than showing any protection 
the reverse occured. Rats given the combination 
developed tumours earlier than those receiving DMH 
alone. These rats also died earlier from more rapidly 
advancing tumours, they commonly developed métastasés, 
which are unusual in this model, and showed a tendency 
to develop primary cancers at sites other than the gut. (74)
Local Injection
Intradermal, subcutaneous or direct injection into the 
tumour with C. Parvum causes negligible toxicity and is 
assumed to act through stimulation of cells in the regional 
lymph nodes. Used in this way there is no effect on the 
size of the liver or spleen nor is there any influence 
on the macrophage producing capacity of the bone marrow.
C, Parvum injected intradermally in the flank contralateral 
to an established transplanted methylcholanthrene induced 
fibrosarcoma has a small anti-tumour effect. However, 
when combined with intraperitoneal cyclophosphamide the 
suppression of tumour growth was much greater than either 
treatment alone. In fact in certain combinations many 
animals were "cured" of tumour. (75) Currie speculated 
that stimulated immune lymphocytes might be protected 
against cyclophosphamide which would then exert a 
proportionately greater effect on the tumour cells.
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Cyclophosphamide has been shown to selectively depress 
the B cell areas of the spleen and lymph nodes. (76)
A proportional increase in T lymphocytes after 
cyclophosphamide was reported with enhanced cell mediated 
immunity. It may be that the combination of C. Parvum 
and cyclophosphamide caused further enhancement.
Local injection of C. Parvum is only minimally effective if 
given at sites distant from tumour, but can cause marked 
inhibition of growth if injected nearby (i.e. where it is 
likely to engage the tumour draining lymph node). This 
is found in both mammary adenocarcinoma (77) and 
mastocytoma. (78) Injection directly into the tumour 
was' most effective of all, but local injection has a 
significant effect provided the lymph node which drained 
the tumour also drained C. Parvum. This was not seen in 
T cell deprived mice, a finding which prompted Woodruff 
and his group to repeat their earlier work using local 
rather than systemic injection of C. Parvum. (79) They 
were able to confirm that the inhibiting effect of C. Parvum 
injected into the tumour noted in their transplantable 
fibrosarcoma was not present in T cell deprived mice.
Animals in whom tumour growth was suppressed by this 
treatment were highly resistant to a second challenge with 
the same tumour. It was also noted that diphtheriods, which 
have no anti-tumour effect when given systemically are not 
active when inoculated directly into tumour.
When C. Parvum was injected along with an inoculum of 
live mouse mammary carcinoma cells tumour growth was normal 
in the initial stages, but at 14 days rapid and complete 
regression supervened. When the injection was delayed 
until the tumour had been established for 14 days rapid 
regressions of the primary and its métastasés occurred.
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Local injection of C. Parvum into the site of the tumour 
or mixed with tumour cells often causes complete 
regression. (79) (53) This is in distinction to its
systemic use where, although suppression of tumour 
growth may result cures are rare. (80)
Combination of C. Parvum and tumour cells
Many attempts to stimulate specific anti-tumour immunity 
have been made using tumour cells whose mitotic capacity 
has been removed, but whose antigenic structure remains 
intact. Commonly a suspension of tumour cells is irradiated 
and re-inoculated either alone or in combination with 
an immune adjuvant. Used in this way C. Parvum has such 
an adjuvant effect (81) and boosts antibody response 
to a variety of antigens. Both IgG and IgM levels are 
augmented in animals.
The simultaneous s.c. injection of irradiated tumour 
cells and I.P. injection of C. Parvum to mice with small, 
but actively growing fibrosarcoma isotransplants caused 
more prolonged remission than either treatment alone. (82)
When the C. Parvum was given 7 days before the irradiated 
tumour cells, rather bhan conferring a beneficial effect, 
tumours grew more rapidly. (83) It appears that even 
in these immunogenic tumours the timing and dose levels 
of both tumour and C. Parvum are critical.
Mice challenged with either subcutaneous (s.c.) or I.V. 
methylcholanthrene induced fibrosarcoma cells derived very 
little benefit when given I.V. C. Parvum 2 days later. 
However, when the C. Parvum was combined with an optimum 
number of irradiated tumour cells and injected into the 
footpads with 6 days of the initial tumour challenge, very
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marked suppression of growth and some cures resulted.
This was only demonstrable in T cell intact animals 
and when the same tumour cells were used for inoculation 
and challenge. The immunity derived is highly specific,
(84)
Mode of Action of Systemic C . Parvum
The anti-tumour action resulting from systemically 
administered C. Parvum may be largely non-specific. This 
action is not abrogated in T cell deprived mice (64, 85) 
and is also partly resistant to treatment with anti­
lymphocyte serum. (70) Nor does it seem likely that 
this action of C. Parvum is dependent on humoral immunity 
as an anti-tumour effect is also seen in experimental 
animals selected for low antibody responses. (83, 84)
After systemic C . Parvum peritoneal exudate cells appear 
in both normal and thymectomised mice which inhibit tumour 
cell growth vitro. (86) This activity disappears
if the cells are first incubated on a glass surface and the 
glass adherent cells excluded from the tissue culture. It 
is also absent when the effector cells are lysed, (implying 
the action is not simply enzymic), or if they are not 
in intimate contact with tumour cells. The anti-tumour 
effect after systemic C. Parvum is paralleled by an increase 
in macrophage mediated phagocytosis and can occur in the 
presence of a high antibody titre against the organism. (87)
Other evidence suggests that the macrophage is the 
important effector cell. The action is still present 
when the peritoneal exudate cells are exposed to 4000 rads 
immediately before incubation with tumour cells. The 
surviving cells are macrophages and display the same anti­
tumour action as non irradiated collections. In addition 
the adherent cells from such collections histologically
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appear to be macrophages and such adherent cells have 
the same anti-tumour activity as the intact collection 
of cells.
Active strains of C . Parvum produce a macrophage 
chemotactic factor which can also activate lysozymes 
within these macrophages. (16) After systemic 
administration the bacterium localises within liver, 
lungs and spleen (88, 7) but the observation that up 
to 25% of the injected dose localised within the tumour 
(88) is denied by other investigators. (7) Selective 
localisation in liver and lungs may contribute to the 
anti-metastatic capacity of systemic C. Parvum.
C . Parvum has been shown to increase the number of 
macrophage progenitor cells in the marrow of stimulated 
animals. This increases the availability of M.P.S. cells.
(19)
Serum lysozyme levels rose after intravenous C, Parvum in 
both normal and tumour bearing animals. (17) Examination 
of the cell population within syngeneic transplanted 
adenocarcinoma showed that C. Parvum increases the numbers 
of Fc receptor bearing cells, but cells capable of 
phagocytosing carbon particles were not increased. (9)
It may be that non phagocytic monocytes were those bearing 
Fc receptors and these immature cells are the major 
effector cell population. (10) C. Parvum induced 
stimulation of bone marrow would lead to efflux of 
macrophage precursors. Using a transplantable mouse 
methylcholanthrene induced fibrosarcoma an anti-tumour 
effect was noted without any effect on Fc receptor positive 
cells within the tumour. (11) In contrast to the 
suggestion that the immature monocyte is the anti-tumour 
effector cell, it has been shown by differential sedimentation
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of peritoneal exudate cells that the anti-tumour cells 
were found to be the heaviest cells i.e. the largest 
most differentiated macrophages. (89)
Mechanism of Action of local C . Parvum
Anti-tumour activity after locally administered C. Parvum 
must be at least partly T cell dependent. Suppression 
of subcutaneous growth of several transplantable murine 
tumours occurs in normal but not congenitally 
immunosuppressed (nude) mice. (90) C. Parvum may act 
as an adjuvant, enabling recognition by T cells of tumour 
associated antigens. However, at the site of C. Parvum 
initiated tumour destruction following its intralesional 
injection there is a massive mononuclear infiltrate 
suggesting that these cells also play a part. (91) It 
may be that C . Parvum evokes a T cell response against 
C. Parvum antigen which causes the release of substances 
capable of producing activated macrophages.
The ability of C. Parvum to suppress the growth of admixed 
tumour cells when given to athymic hosts was abrogated 
by concomitant administration of silica. This implies 
that a phagocytic cell is required either to destroy or 
assist in the destruction of the tumour cells. (92)
In summary
Systemically administered C. Parvum results in a moderate 
anti-tumour effect with considerable effect against 
developing metastasis in some models. The main effector 
cell is the macrophage and a generalised stimulation of 
the reticuloendothelial system results from this form of 
treatment, which requires a relatively high dose of the 
bacterium. There is augmented antibody production and the
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marrow is stimulated producing increased numbers of 
macrophage progenitor cells.
The anti-tumour effect does not appear to require 
complement and is not dependent on T or B cell co­
operation. However, there is evidence that the sub­
population of T^ cells is required. Anti-tumour activity 
is non specific in nature.
On the other hand locally administered C . Parvum acts 
mainly through T cells and macrophages. Its effect is 
to produce highly specific anti-tumour immunity, effected 
via the regional lymph nodes. Only low doses of C. Parvum 
are required. There is minimal systemic effect as a result 
and the marrow and reticuloendothelial system are not 
markedly stimulated.
C . Parvum in Humans
The use of a new agent which might be expected to cause 
toxic side effects in the treatment of cancer is 
proceeded by a phase 1 study. This means establishing the 
dose of the drug in a limited number of patients suffering 
from advanced malignancy. These studies do not set out to 
evaluate therapeutic benefit. Phase 1 studies using 
intravenous C . Parvum suggested that it could be given 
safely in doses of up to 10 mg/m^. (93, 94, 95)
side Effects
In all studies where the bacterium has been given 
intravenously the dose has been suspended in a diluting 
volume of fluid, usually normal saline. The dose given 
has been based on the estimated surface area of the patient, 
calculated with a nomogram using the height and body weight.
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In most reported séries the dose has been between 5 and 
10 mg/m . Infusion usually takes between half an hour 
and four hours. Side effects are unusual in the first 
two hours. Chills, fever and occasional rigors are 
common between two and four hours.
These symptoms can be partly controlled with extra 
blankets and aspirin. However, they can neither be 
prevented nor completely controlled. Headaches and 
musculoskeletal aches and pains are also often experienced. 
Again aspirin helps. Nausea and vomiting is common, but 
can largely be controlled by the prior administration of 
anti-emetic drugs. The overall impression of this phase 
of the reaction is of an influenzal-like illness,
A more serious side effect is the marked fluctuation in 
blood pressure that occurs, (95, 97) although some have 
not found this to be a problem. (93) Both hypotension 
and hypertension can develop and they may follow in 
sequence. This side effect had been found during phase 1 
studies and as a result caution was taken over patient 
selection for this treatment by all investigators. In 
most patients these blood pressure fluctuations can be 
managed conservatively and increasing the infusion rate of 
simple fluids usually controls the hypotension. However, 
in our own series one patient died of an acute myocardial 
infarction 24 hours after a period of C. Parvum induced 
hypotension. (95) Hedley and Currie reported a 
very similar mortality in their treatment of a patient 
suffering from malignant melanoma. (98) Although, in their 
case the precise cause of death was unclear it seems likely 
that it was similar to ours. The subsequent rigid 
exclusion of patients with any suspicion of cardio respiratory 
disease makes the systemic use of C. Parvum unsuitable for 
a large number of patients suffering from malignant disease.
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While some workers have found that hydrocortisone will 
prevent these fluctuations in blood pressure (93) others 
have not. (96) Moreover hydrocortisone may suppress 
macrophage function thereby interfering with the proposed 
mechanism of C. Parvum induced anti-tumour activity.
Another serious side effect is that of confusion which 
did not appear to be directly due to hypotension. (93,
94, 96) Patients in our series have not been known to 
suffer from cerebral disease or métastasés and confusion 
has only been found in two patients. However, when the 
drug was used in the treatment of patients suffering from 
known cerebral métastasés severe CNS side effects occurred 
in two. (93) One became aphasie with a hemiparesis then 
recovered. The other patient became aphasie after a fit 
and died. This was in spite of prophylactically given 
hydrocortisone, which this group used in order to minimise 
side effects. A similar death occurred in a British study 
(97) where the clinical picture suggested cerebral oedema. 
It was suggested that as biopsies from these tumours showed 
acute inflammatory oedema with histiocytic infiltration, 
the presence of an intracranial tumour should be a contra­
indication to the use of C. Parvum.
Fisher also gives an isolated report of a patient developing 
a proliferative glomerulonephritis and renal failure after 
systemically given C. Parvum. (93) Lastly there is an 
increased susceptibility to viral infections, particularly 
herpes zoster and herpes simplex.
When C, Parvum is given intradermally or subcutaneously 
very few side effects have been reported. Occasionally 
transient painful swelling of the lymph nodes draining the 
site of inoculation has occurred.
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Haematoloqical Alterations after C. Parvum
Systemically administered C. Parvum causes the 
following haematological alterations :-
Haemoglobin: Most workers do not comment on the haemoglobin
level after systemic C. Parvum. However, a fall of up to 
2 G with an increased reticulocyte count has been reported, 
(99, 94)
Monocytes: Some workers have found that blood levels of
monocytes drop precipitously within hours of treatment then 
slowly rise to peak at greater than normal levels some 14 
days after injection. (96, 99, 23) However, others did 
not find this. (100) No alteration in the serum level of 
the macrophage enzyme lysozyme follows C. Parvum therapy. 
(25, 99)
Lymphocytes; Lymphocytopaenia occurs within hours of the 
infusion. (25, 99 23)
T cell function has been analysed in several studies.
While T cell numbers were decreased in the study of 
Micheson and Castro (,101) others found no change. (100)
The response of T cells to polyclonal activation with the 
plant mitogens PHA and ConA has been extensively used as 
an in vitro test for cell mediated immunity. Investigations 
using lymphocytes from patients who have received C. Parvum 
lead to confusing results.
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An increased lymphoblast response was found after 
intravenous C. Parvum in doses from 1-5 mg. This 
correlated with an increased skin response to a battery 
of recall antigens. (23) However, the responses were 
suppressed more often than they were increased and 
the results were inconclusive. A slight increase in 
these responses was seen after intravenous C. Parvum 
in a dose of 2 mg/m given to patients suffering from 
malignant melanoma. However, no claims of significance 
were made. (102)
Micheson and Castro found that these responses were 
significantly reduced in their patients all of whom 
suffered from advanced cancer. Further suppression 
occurred after systemic C. Parvum given at a dose of 
10 mg/m^. (101)
Similar depression was noted in patients with treated
2colorectal cancer receiving C. Parvum 5 mg/m I.V. Here 
the suppressed values were statistically significant when 
measured 3 hours after infusion. (96)
Neither culture of lymphocytes in vitro with C. Parvum nor 
lymphocytes taken from patients with breast cancer treated 
with C. Parvum showed.any consistent changes. These patients 
were receiving alternating courses of chemotherapy and 
C. Parvum, so that the chemotherapy might have influenced 
the lymphocyte responses and obscured the effect of C. Parvum, 
(103)
This confused picture makes it extremely difficult to draw 
conclusions. It is quite likely that much of the confusion 
is due to the large number of variables involved. For 
example, the patients were suffering from a variety of 
different malignancies and were advanced in some series 
while in others all known tumour had been extirpated.
34
Different doses of C. Parvum were used and the 
lymphocytes were analysed at variable times after the 
infusion. However, it does seem likely that any 
lymphocyte stimulation was modest and not of real 
significance.
Immunoglobulins: Serum levels of immunoglobulins are
not altered by C. Parvum treatment in humans. (93, 94,
102, 100) An increase in the IgG subclass IgG^ has 
been reported. (101) (104)
The overall impression is that humoral immunity is 
unlikely to be stimulated by this treatment. This is in 
contrast with the increase in IgG and IgM noted after 
its use in experimental animals. (105)
Skin Testing: The poorer prognosis of patients who are
anergic to skin test antigens has been described. Although 
C . Parvum treatment occasionally converts the patients 
response from negative to positive, usually no alteration 
occurs. (100, 93, 94)
Clotting Factors; Systemically administered C. Parvum 
causes considerable alterations in blood clotting factors.
A marked increase in fibrinolytic activity occurs within 
2 hours of infusion returning to normal levels by 4 hours.
A corresponding increase in the level of fibrin degradation 
products is noted, although there is no alteration in the 
total fibrinogen level. (106, 101) Whether this is of 
any therapeutic benefit is open to doubt. It has been 
argued that fibrinolysis diminishes the likelihood of 
circulating tumour cells successfully implanting to develop 
into a metastasis.
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Although evidence has been presented suggesting that 
serial infusions lead to a state of disseminated 
intravascular coagulation this has not been clinically 
apparent in patients so treated. (101)
Biochemical change: During the 5 hours following the
intravenous infusion of C. Parvum there is a rise in
the serum levels of glucose, lactate and Ketone bodies 
and a fall in serum alanine. Bilirubin, glutamyloxalo- 
acetate transferase and urea are elevated 24 hours after 
the infusion while albumin and cholesterol are lowered.
(107) These alterations are similar to those seen after 
bacterial infections of the liver with acute parenchymal 
cell damage.
Phagocytic Function: Since stimulation of the RES was
the primary observation in experimental animals injected 
with C. Parvum Attie devised a measurement of this function 
suitable for patients. (22) Serial measurements of the 
level of serum radioactivity after the injection of radio- 
labelled microaggregated human albumin was performed.
This gave a measurement of the rate of disappearance 
of the test substance. By comparing this rate with 
standard controls a measure of the uptake of the substance 
was obtained. These studies appeared to confirm that when 
C. Parvum was given to these patients, all of whom suffered 
from cancer, increased phagocytosis occurred.
Macrophage Function: Hedley and Currie have examined
monocyte preparations obtained using Ficol-hypaque gradients 
according to the method of Boyum. (98) These preparations 
were made from blood obtained from patients suffering 
from disseminated malignant melanoma or those with probable 
micrometastatic malignant melanoma. The patients were 
being treated with alternating courses of the chemotherapeutic
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agent imidazole carboxamide (D.T.I.C.) and intravenous 
C. Parvum in doses ranging from 700 ;ag to 7 mg. Three 
different ways of testing the monocytes have been used.
Monocyte Maturation: The in vitro capacity of monocytes
to develop into colonies when incubated under favourable 
conditions.
After C . Parvum the number of colonies which developed 
was not increased when the tested monocytes were obtained 
from patients suffering from general dissemination of 
disease. However, the number was significantly increased 
in the samples taken from patients with microscopic 
evidence of metastatic spread into the regional lymph 
nodes. Moreover mitoses were sometimes seen in the 
culture plates, normally a most unusual phenomenon,
Nitro Blue Tétrazolium Reduction: The reduction of the
dye nitro blue tétrazolium is taken to be a direct measure 
of the activity of the hexose monophosphate shunt and 
hence the metabolic rate of the cell. Monocytes from 
patients who had received C . Parvum showed a greatly 
increased reducing capacity.
51Lytic Capacity: The rate of release of Or from antibody
coated autologous red blood cells bearing this radio­
isotope was measured after incubation with patient's 
monocytes. Monocytes from C. Parvum treated patients 
increased release suggesting that their lytic capacity 
was increased.
These iui vitro tests suggested that C. Parvum is capable 
of "activating" macrophages. Similar results were 
obtained when the bacterium was inoculated by the safer 
intradermal route.
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Interferon
It has been suggested that C. Parvum increases natural 
levels of interferon production and this could be a 
mechanism of anti-tumour action. Serum interferon levels 
were increased after subcutaneous C. Parvum given to 
healthy volunteers. (108) In this study there was also 
enhanced jui vitro lymphocyte mediated cytotoxicity 
against K 562 leukaemia and RAJI lymphoma cells. However, 
the subcutaneous route is not usually noted to have 
particularly marked effects on cell populations and these 
studies were only performed on 4 volunteers.
In another recent study the proliferative rate of T 
lymphocytes and their interferon production was increased 
by the addition of C. Parvum to the culture, (109) This 
effect was maximal when the C . Parvum was added 7 days 
after the initiation of the culture. When C. Parvum is 
added to macrophage cultures no such interferon production 
occurs, nor do C. Parvum incubated T cells show further 
enhancement of interferon production when admixed with 
macrophages.
Another method of stimulating interferon production is to 
use the polyvalent mitogen PHA. Lymphocytes stimulated 
by both PHA and C. Parvum show greatly enhanced interferon 
production which is more than the sums of the two on their 
own.
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Results of C . Parvum treatment in human malignancy
Clinical trials using C. Parvum against human malignant 
disease began in France in 1967. (95) Israel reported
414 human cancers treated with combined chemotherapy 
and iramunotherapy.
In this early study the bacterium was given by weekly 
subcutaneous injection in a dose of 4 mg. 5 drug 
combination chemotherapy was given twice a month, the 
combination comprising cyclophosphamide, methotrexate,
5 fluorouracil, vinblastine and streptonigrin. This 
combination of treatments was used in the treatment of 
various disseminated solid cancers, the majority being 
from primaries in the lung or the breast. In the combined 
treatment group double the number of patients were alive 
at 6, 12 and 18 months. C. Parvum treated patients also 
had a lower incidence of leukopaenia and fewer 
interruptions of chemotherapy.
Israel's group also reported the results of I.V. C. Parvum 
in 12 patients with disseminated disease. 4 of the 
patients had a partial response of a very limited duration.
Using a mixture of autologous irradiated tumour cells
mixed with C. Parvum, McCune reported minimal side
effects. (110) The dosage employed was 30 mg C. Parvum 
. 7mixed with 10 tumour cells. Weekly subcutaneous inoculations 
were used until all the vaccine was used up. Although this 
was a phase 1 study in 15 patients with a heterogenous 
group of malignancies a prolonged regression of disease 
was noted in 1 patient who was suffering from pulmonary 
métastasés secondary to a resected renal carcinoma.
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Combination chemotherapy with or without C. Parvum in
2
a dose of 5 mg/m given subcutaneously was given to 
patients suffering from advanced breast cancer. The 
group receiving both treatments showed an improved 
survival at 11 months. These patients suffered less 
bone marrow suppression so that there were fewer 
interruptions of cytotoxic treatment. (99)
While C. Parvum has been used quite extensively in 
patients suffering from advanced cancer of the colon 
(111, 112) no definite evidence of benefit has been 
obtained. In many of these trials C. Parvum was given 
in combination with cytotoxic drugs. The resulting 
difficulties in interpretation are increased because of 
the lack of proper randomisation and the use of historic 
controls in some of the studies. Many of these trials 
have not yet been completed.
A randomised controlled study in the treatment of patients 
with Stage III lung cancer has been reported. (113)
All patients received cytotoxic chemotherapy with adriamycin, 
cyclophosphamide, cis-platinum and vincristine. In 
addition they were randomised to no treatment, immunotherapy 
with MER or immunotherapy with I.V. C. Parvum. The
C. Parvum treated group had a stastically significant 
improvement in survival rate over the other two groups.
This study has been criticised on the basis of lack of 
comparability between the treated groups.
There is also a preliminary report suggesting benefit from 
combining systemic C. Parvum with chemotherapy in patients 
with Stage III ovarian cancer. (114) In this report the 
patients had as much tumour removed as possible prior to 
receiving chemo/immunetherapy. Nearly a third of the 
patients received C. Parvum alone and they all died within
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a month of operation. None of the deaths were apparently 
directly related to C. Parvum treatment. Four out of 
thirty nine patients received the combined treatment and 
were alive and free of evidence of disease 9-12 months 
after operation.
There has been no unequivocal evidence of clinical benefit 
following the clinical use of C. Parvum.
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Histochemical Staining of some Acid Hydrolases
The aim of enzyme histochemistry is to accurately demonstrate 
the localisation within tissues of the enzyme being 
studied. Alterations in concentrations and localisation 
of enzyme may be characteristic of disease processes 
and may enable an analysis to be made of functional cell 
populations. Both fixed tissue and circulating members 
of the M.P.S. contain high concentrations of acid 
hydrolase enzymes and various stain techniques can be. 
applied in their investigation. Activation of these cells 
may increase the amounts of enzyme present, while 
participation in metabolic processes eg. phagocytosis, 
cell killing and lysis may lead to depletion. Unfortunately 
the plethora of enzymes present within these cells makes 
it difficult to select those most worthy of study. In an 
ideal enzyme staining reaction the substrate used is specific 
to the enzyme being studied. The product of the enzyme - 
substrate reaction is stable, non diffusible and can be 
clearly and accurately recognised. This ideal reaction is 
probably rarely achieved but various techniques render the 
method sufficiently accurate to permit reasonable inferences 
to be made about enzyme localisation.
Fixation: (115, 115) ,Depending on the enzyme being studied,
prior fixation may improve results. For instance fixation 
with formal chloride for 12 hours renders /6 glucuronidase 
less diffusible and hence staining reactions after this 
treatment give a more precise indication of enzyme 
localisation. On the other hand acid phosphatase diffuses 
out of the tissues during fixation in formol calcium and 
Pearse suggests that here the best results are obtained 
using raw frozen sections. (117)
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The results of histochemical staining of enzymes may
be influenced by several factors; ,
1. Mitochondrial enzymes begin to diffuse within a few 
minutes of ischaemia. Although minor degrees of this 
diffusion may not be significant, if allowed to 
proceed the validity of enzyme localisation would
be suspect. This process can be halted by rapid 
freezing but the formation of ice crystals can 
adversely affect histo-chemical reactions. Enzyme 
staining reactions should be performed on the freshest 
tissues possible, unless prior fixation is considered 
preferable.
2. The pH,at which the staining reaction is to be 
carried out may also be critical. (118) For example 
the acid phosphatases are a group of iso enzymes 
having their maximal activity over separate pH ranges. 
At the pH of 5 which is optimal for most acid 
phosphatase activity the rate of coupling is too slow 
to prevent diffusion, so a compromise pH of 5.5 is used,
3. Coupling reagents like pararosanilin may also inhibit 
enzymes.
4. The substrate should be water and lipid soluble with a 
low molecular weight. This allows rapid diffusion 
into tissues permitting a high ratio of substrate 
enzyme. In these circumstances the reaction follows 
zero order kinetics and the reaction product accurately 
reflects the amount of enzyme present.
The substrate should also be capable of being easily 
hydrolysed at a pH and temperature in the optimum 
range for the enzyme activity.
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5. Substantivity refers to the affinity of the Primary 
enzyme/substrate reaction product to protein. This 
is important since a highly substantive complex will 
not diffuse away from the site of the primary 
reaction. If this is not the case the final reaction 
product will diffuse leading to poor localisation. 
However, if substantivity is too high there is a 
risk of binding to specific proteins leading to false 
localisations.
The techniques used in the study of enzymes follow in the 
.appropriate sections. The methods for non specific esterase 
and acid phosphatase are examples of simultaneous capture 
coupling. Here the enzyme/substrate complex is linked to 
hexazotised pararosanaline as it forms giving a stable 
coloured precipitate. yg glucuronidase has been stained 
by a post coupling capture method, again using hexazotised 
pararosanaline but adding this in a separate step subsequent 
to the enzyme substrate reaction.
The Macrophage
In 1868 Paul Langerhans described a dendritic cell in the 
human epidermis which stained with gold chloride. (119)
He believed this cell to be a neural element and described 
it as having processes passing into the dermis. This may 
have been the first description of the morphologically 
diverse group of cells which make up the reticuloendothelial 
or mononuclear phagocyte system. (MPS) There are now so 
many roles ascribed to this group of cells that some 
investigators believe there must be distinct sub-populations 
serving separate functions. (119) The diversity of 
functions ascribed to the macrophage make a succinct 
description of this cell series difficult. They are found 
throughout the body either as circulating mononuclear
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phagocytes (blood, peritoneal, alveolar, lymph) or 
fixed tissue macrophages and histiocytes (Kupffer, 
reticular, dendritic and mesangial cells).
Cells of the M.P.S, are capable of engulfing foreign 
particulate material (including bacteria) by phagocytosis. 
This function requires the co-operation of the complement 
system and B cells. Phagocytosis is a metabolically 
active phenomenon and is accompanied by increased oxygen 
consumption. There is also increased activity of the 
hexose monophosphate shunt and the formation of hydrogen 
peroxide. (120) Engulfed materials contained within 
vescicles are fused with lysozomes and digested. M.P.S, 
cells, having a high metabolic activity, have a well 
developed endoplasmic reticulum, Golgi apparatus and 
numerous mitochondria. (121) Peroxidase activity is 
usually present and a large variety of enzymes can be 
demonstrated. (122)
The Macrophage and Cancer
Macrophage mediated killing of tumour cells in vitro has 
been repeatedly demonstrated since first shown by Gorer 
in 1956. (123, 124) The role of the M.P.S. in
spontaneously arising cancers is not known. (125)
Before examining the evidence that macrophages exert an 
anti-cancer action some terminology should be defined.
Normal Macrophage: These cells obtained from non activated
normal animals have no anti-tumour effect vitro. (126)
Immune Macrophage: Peritoneal macrophages from animals
which have previously been challenged by the intraperitoneal 
inoculation of tumour cells are capable of lysing the same
45
tumour cells. This lysis is highly specific but has 
no implications about the mechanism of cytolysis. (126)
Armed Macrophages: When macrophages from non immune
animals are incubated with immune lymphocytes they are 
rendered cytotoxic for specific target tumour cells.
Cell lysis is not achieved. The lymphocyte factor which 
confers this cytotoxic capacity is called "specific 
macrophage arming factor" (S.M.A.F.). (127)
Activated Macrophage: Macrophages from some animals
inhibit tumour cell growth non-specifically. This is 
seen more commonly after stimulation with bacterial 
products (128) chronic infection with intracellular 
parasites (129) or nematodes, (130) interaction with 
polyanions such as endotoxin or double stranded RNA (131) 
and stimulation by B.C.G. and C. Parvum. (129)
Anti-tumour activity can be studied in three ways:-
1. The anti-tumour effect of macrophage stimulating 
agents.
2. Macrophages within tumours.
3. The anti-tumour effect of macrophages injected after 
tumour cells.
1. The first of these modes of action has'been separately 
considered under the heading "C. Parvum as an anti-tumour 
agent."
2. Macrophage within tumours
Alexander has shown in rats that the presence of large
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numbers of macrophage within solid sarcomata is a 
favourable prognostic indicator. These tumours 
metastasize much less readily than those with a lower 
macrophage content. (132) Precisely what role these 
cells have within the tumour is not known. Elucidation 
of their action would be possible if a strain of animal 
deficient in M.P.S. cells was available. Such a defect 
might be incompatible with life and the best alternative 
at present is to use silica, carageenan or anti-macrophage 
serum. These agents are all toxic and may also influence 
T lymphocytes. In addition sublethal doses do not reduce 
tumour macrophage content.
Hopper and Pimm have shown that the mechanism of action 
of B.C.G. when injected into tumour deposits is dependent 
on macrophages. (133) Locally administered B.C.G. 
suppresses growth of syngeneically transplanted rat 
tumours. This treatment is successful even in immune- 
suppressed rats and nude mice. Treatment with the 
macrophage toxin silica abrogates this effect of B.C.G. 
in both these models. These authors also found a correlation 
between the macrophage content of tumours and the 
capacity for suppression of growth by B.C.G. contact.
A method (134) of preparing tumour cell suspensions has 
been described by Evans. Using this technique macrophage 
numbers can be counted, based on the recognition of 
functional characteristics like adherence to glass and 
phagocytic capacity. Macrophage concentrations within a 
variety of experimental tumours vary between 4% to 56% of 
the total cell numbers. These cells were shown to have 
been derived from circulating host monocytes. Using this 
method Eccles and Alexander studied the macrophage contents 
of a variety of chemically induced rat fibrosarcomata to 
see if this was related to the biological behaviour of the
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tumours, particularly the ability to metastasize. (135) 
Hooded rats were depleted of T cells by either prolonged 
drainage of thoracic duct lymph or thymectomy and 
repeated whole body irradiation before tumour implantation. 
A benzpyrene induced fibrosarcoma was transplanted 
intramuscularly in the hind limbs and excised 14 days 
later when the tumour macrophage content was assessed.
T cell depletion considerably lowered the macrophage 
concentration, led to increased métastasés and reduced 
survival.
A considerable degree of co-operation between T cells and 
macrophages appears to influence the growth of this 
particular experimental tumour. Alexander suggests that 
the macrophage both attempts to prevent metastatic spread 
and phagocytoses tumour breakdown products, thereby 
reducing the amount of soluble tumour antigen released 
into the circulation.
3. The anti-tumour effect of injected macrophages
Macrophages inoculated after a tumour cell challenge can 
exert an anti-tumour effect. This effect can be seen 
both after injection of macrophages at the tumour site or 
at a distance from the tumour. One criticism of this 
approach is that the macrophages are obtained from 
peritoneal exudate collections and are not necessarily 
tumour associated.
Macrophages injected at the tumour site
Syngeneic immune macrophages : Immune macrophages can be
obtained from the peritoneal cavity of mice exposed to the 
L5178Y tumour. Syngeneic mice who received an intra­
peritoneal dose of these cells after an intraperitoneal
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inoculation of the same tumour survived twice as long 
as controls. (136)
Syngeneic armed and syngeneic activated - armed macrophages 
Normal peritoneal cells are armed m  vitro by incubation 
with lymphocytes. Activated - armed macrophages are 
prepared by vitro incubation with immune spleen cells 
and target cells (in this case lymphoma cells). These 
cells demonstrated increased cytotoxicity in. vitro. They 
also prolonged survival when given to syngeneic mice after 
they had received an intraperitoneal inoculation of the 
same lymphoma cell. (137)
Allogeneic immune and hyperimmune macrophages: Immune
macrophages were obtained from the peritoneal cavities of 
mice which had previously received intraperitoneal SL2 - 
lymphoma cells. These cells were then used to immunise 
mice of a different strain against the same tumour. 
Immunised mice had considerably prolonged survival. 
Lymphocytes contaminating the peritoneal exudate cells had 
no anti-tumour effect on their own but did enhance the 
macrophage effect. (137)
Syngeneic activated macrophages: Macrophages become
activated by vitro .culture with Bl6 melanoma cells or 
supernatants from culture of these cells. Intravenous 
injection of these activated macrophages suppressed the 
development of pulmonary métastasés when given after I.V, 
challenge with the Bl6 melanoma. Intra-peritoneal 
macrophages had no such effect. This could be regarded as 
a local effect since the macrophages are cleared by the 
lung after I.V. inoculation. (138)
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Macrophages injected at a distant site
Activated Macrophage: In the experiment just quoted
intraperitoneal administration of activated macrophages 
had no effect on the development of pulmonary métastasés. 
(138)
Macrophage in immune spleen cell suspensions: Cell
suspensions of spleens taken from immune animals will 
suppress tumour growth if given at a different site. This 
effect is partly dependent on macrophage since it does not 
occur after treatment with silica. However, the results 
are equivocal. (137)
There is little firm evidence that activated macrophages 
have anti-tumour effects when given at a site distant from 
the tumour. This does not imply that in all naturally 
occurring cancers the circulating macrophages cannot be 
activated on reaching the tumour site.
The mechanism of macrophage mediated cell killing
The enhanced cytolytic capacity of macrophages by specific 
mechanisms like S.M.A.F. or antibody is directed against 
a unique target cell type. (139) Non specific activation, 
for example by bacterial endotoxin or C. Parvum, confers 
widespread cytotoxic capabilities against a variety of 
target cells. (140) Whatever the mechanism, cell to cell 
contact is probably required to cause tumour cell death.
Such intimate intercellular adherence permits the release 
of lysozomal enzymes causing cell destruction. Arming 
factors, antibodies, complement and macrophage activation 
may alter the macrophage cell surface enabling this intimate 
contact to occur. (141) Apart from release of high 
concentrations of toxic enzymes from lysozomes, cytoplasmic
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peroxidases could also cause destruction.
Another suggestion is that macrophages release arginase 
which has the effect of depleting the tumour cell millieu 
of arginine. (142) Tumour cells which are unable to 
stop metabolising in spite of the lack of essential 
amino acids, literally die of "starvation".
Macrophage function in tumour bearing hosts
Reports of studies on monocyte and macrophage function in 
both human and animals cancers are at first sight confused. 
During tumour growth many macrophage functions are 
enhanced including the ability to kill tumour cells in 
vitro, (143) m  vivo resistance to tumour cell challenge, 
(144) and macrophage production by the bone marrow. (145) 
Depression of macrophage function is commonly seen in 
advanced cancer. (146) While it appears that during the 
early stages of disease macrophage function is enhanced, 
this is not the case in advanced cancers. Using the Lewis 
lung cancer as an experimental model in C57 BL mice, Otu 
has examined macrophage function at varying stages of 
disease. He assessed the rate of clearance of colloidal 
carbon, chemotactic locomotion of macrophages and the rate 
of formation of macrophage colonies from bone marrow. All 
these functions were depressed for the first few days after 
tumour transplantation. Subsequently they were enhanced 
until, in the presence of extensive disease, they were once 
more depressed. (147) Serum from mice previously grafted 
suppressed the in vitro formation of marrow derived 
macrophage colonies suggesting that a soluble factor may 
be responsible for macrophage inhibition in cancer.
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This varying response may explain the apparently 
conflicting results obtained in patients with malignant 
disease. Early suppression by cancer cells could allow 
the tumour to become established. Later the host 
macrophages increase in numbers only to become suppressed 
again in the face of over-whelming malignant disease.
Interference with systemic macrophage function may also 
enable metastatic spread. Soluble tumour antigens, 
antigen-antibody complexes or small non specific factors 
could be responsible for paralysing the macrophage response 
(148, 144)
It is simplistic to view the M.P.S, as an anti cancer 
mechanism in isolation. The role of complement, antibody 
and arming factors have been mentioned. Lymphocyte 
ability to recognise foreign tumour cell antigens and the 
subsequent release of lymphokines enhances the accumulation 
of M.P.S. cells. (149, 141) It may be that it is the 
complexity of the normal tumour defence mechanism that has 
prevented its elucidation.
The origin, circulation and fate of mononuclear phagocytes
The classic work of Vqlkman and Gowans has established 
the bone marrow origin of cells of the M.P.S. (150) 
Monocytes arise from promonocytes in the bone marrow and 
enter the general circulation (151, 152) eventually 
passing into the tissues as mature macrophages. Monocytes 
are able to migrate to the extravascular spaces by 
amoeboid movements between endothelial cells of venules. 
(153) Cells of the M.P.S. do not migrate through the post 
capillary venules of lymph nodes. This is in contrast to 
the major route of recirculation of lymphocytes from blood 
to lymph as described by Gowans. (154)
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Production
M.P.S. cells within the bone marrow can be classified 
as promonocytes and monocytes. (151) Promonocytes 
develop from primitive pluripotential progenitor cells. 
Promonocytes have been shown by H thymidine labelling 
studies to be the proliferating cells and the monocytes 
non dividing. This study was performed under normal 
steady state conditions. Similar labelling studies 
showed that the monocytes were the progeny of division 
of promonocytes and that two such daughter cells are 
produced for each mitosis.
Monocytes then enter the blood stream where they either 
remain in circulation or migrate to tissues or coelomic 
cavities. During a chemically induced peritonitis a 
threefold increase in blood monocytes with a x2.5 increase 
in peritoneal macrophages is noted. (155) The monocytosis 
is due to increased production by marrow promonocytes and 
the increased peritoneal macrophages all come from this 
source., There is no local proliferation of peritoneal 
macrophages.
The relationship between the peripheral blood monocyte 
and the tissue macrophage has been demonstrated by some 
celebrated names in pathology. Metchnicoff, Aschoff and 
Florey have all made major contributions.
The function of the circulating monocyte is diverse and 
unclear. It is certainly rather more than a short lived 
cell in transit. It forms the major defence against 
intracellular bacteria, fungi and parasites, plays a part 
in antigen processing and interacts with lymphocytes in 
cell mediated immunity. (119) The monocyte may also 
provide a defence system against some tumours. (156, 157)
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Laboratory investigations into the function of 
circulating monocytes have been hampered by difficulties 
in obtaining pure samples of these cells. In normal 
blood the monocytes make up approximately 1% of the 
total white cell population. More concentrated 
preparations can be obtained by using Ficoll-Hypaque 
density gradients which allows separation of the white 
cells of the blood into their constituent sub­
populations. Samples obtained by this method may 
contain cells of another sub-population and caution must 
be exercised in the interpretation of results obtained 
using these supposedly pure preparations. (158)
Tissue Macrophages
The Kupffer cell has been regarded as the classical 
fixed tissue macrophage. Its position in the liver 
sinusoids means that it is ideally situated to clear the 
blood of gut derived micro-organisms and endotoxins.
They also remove other gut derived antigens, antigen/ 
antibody complexes, chylomicrons and senescent red 
cells. (159)
Kupffer cells originate in the bone marrow. (160)
There is debate about -the capacity for these cells resident 
in the liver to divide. (160) Under normal circumstances 
the rate of incorporation of H  ^thymidine by Kupffer 
cells is less than 1.5% of the cell population.
It is therefore unlikely that they synthesize sufficient 
DNA for mitosis. (159)
Studies on patients after liver transplantation have 
provided convincing evidence for the bone marrow 
origin of Kupffer cells. Three months after the 
transplant the hepatic Kupffer cells are of recipient 
origin. This is clearly shown by sex chromatin studies on 
liver biopsies when donor and recipient are of different 
sex. (159)
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Stimulation by C. Parvum causes an increase in Kupffer 
cell number. There is some argument about the origin 
of the newly formed cells. Some workers claim that 
liver Kupffer cells retain the capacity to divide. (13) 
Others argue that the dividing cells are monocytes only 
recently recruited from the bone marrow. (161)
The fate of effete macrophages under normal circumstances 
is unknown. Macrophage death may occur as the result of 
endocytosis of toxic material. Attempts at mitosis may 
be self destructive as gross chromosomal abnormalities 
often appear at the first division. They may also form 
multinucleate giant cells. (153) It is not clear to 
what extent the tissue macrophage retains mobility.
M.P.S. cells within the lymphatic system
The cell population of lymph is altered by its passage 
through a lymph node. Peripheral (afferent) lymph contains 
a varying population of M.P.S. cells. Lymphatics leaving 
the liver are termed afferent prior to reaching lymph 
nodes. These afferent liver lymphatics can be cannulated 
in the sheep. (162) Large numbers of cells are harvested 
(up to 2 X  10^/ day), approximately 20% of which are members 
of the M.P.S. These cells are not seen in the efferent 
lymph leaving the regional lymph nodes.
In lymph afferent to the popliteal lymph node in rabbits 
approximately 40-50% of cells belong to the M.P.S. Only 
10% of these cells show phagocytic capacity, (measured by 
uptake of colloidal carbon) and 3% show Langerhans 
granules which are classically seen on ultrastructural 
studies of the deep layers of the epidermis.
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Cells of the M.P.S. do not normally appear in thoracic 
duct (efferent) lymph. Indeed lymph obtained from 
thoracic duct fistulae has been used experimentally 
as a sample of pure lymphocytes. Poser has shown that 
this is not absolutely true. (163) During chronic 
lymph depletion from rats with cannulae within the 
thoracic duct he showed that M.P.S. cells are found at 
varying time intervals after cannulation. He could not 
explain the great variation in the numbers of these cells 
obtained. In some animals (25%) there were no M.P.S. 
cells in the lymph, whilst in others they appeared soon 
after commencement of thoracic duct drainage, 72 hours 
after cannulation 0.24% of the total cells were members 
of the M.P.S., Poser also demonstrated that these cells 
might originate in the peritoneal cavity of the animal.
A new experimental rat model has been described as the 
result of work carried out in the Sir William Dunn School 
of Pathology in Oxford. Total extirpation of the 
mesenteric lymph nodes of experimental rats is performed. 
At least six weeks later, after allowing time for healing, 
cannulation of the thoracic duct is performed. The lymph 
obtained contains cells of the M.P.S. (164)
This model enables studies to be made on M.P.S. cells 
which are assumed to have been obtained directly from the 
gut wall. If this postulate is true a unique opportunity 
exists for dynamic studies on gut associated M.P.S. cells.
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Materials and Methods 
Animals Used
Female Wistar rats weighing 100-250G have been used in 
this study. This strain was selected in view of its known 
susceptibility to the carcinogenic effects of 
dimethyIhydrazine dihydrochloride. Specific pathogen 
free rats were supplied by Olac laboratories, Bicester, 
Oxon, and Messrs. Banting and Kingman, Aldborough, Hull.
On receipt the animals were housed in a conventional 
animal unit. Rats undergoing carcinogen tumour induction 
were kept in separate cages with wire grid floors. This 
allowed droppings and urine which were possibly 
carcinogen contaminated to pass through into a collecting 
tray. The rats were fed with standard pelleted rat diet.
Corynebacterium Parvum
C. Parvum was provided as a generous gift by Dr. T. J. 
Priestman of the Burroughs Wellcome Medical Foundation, 
Beckenham, Kent. The bacterium is formalin killed and 
made up as a suspension in 0.01% thiomersal as a 
preservative. Vials containing 7 mg of the dry weight 
of the organism are made up to 1 ml with preservative. A 
fresh vial was used for each experiment.
Working Solutions
The following working solutions were used:
Dulbecco A & B (D.A.B.) : Phosphate buffered saline was
made by adding a one gram tablet of Dulbecco A (Oxoid, 
London) to 100 mis of distilled water. This was 
converted to the fully buffered isotonic solution DAB at
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a pH of 7.3 by the addition of 0.5 ml of mineral salts 
(Dulbecco B) to each 100 ml.
Foetal Calf Serum (F.C.S.)
F.C.S. (Gibco bioccult. Paisley) was used as a source of 
opsonins and complement during phagocytosis of sensitised 
sheep red blood cells. It was also added to DAB in a 
concentration of 10% and this solution used for resuspending 
cell pellets after centrifugation. This method has been 
found to prevent clumping of cells and also minimises the 
loss of cells during repeated centrifugation.
Trizma Ammonium Chloride (A.C.T.)
A.C.T. was used to lyse red blood cells. White cells 
are less susceptible to this lysis and, provided exposure 
is not prolonged, no damaging effects result. A.C.T. was 
prepared by dissolving 3.74 G of ammonium chloride in 
450 mis of distilled water then adding 0.103 G of Trizma 
base (trishydroxymethyl aminomethane. Sigma Chemicals,
Poole) dissolved in 50 mis of distilled water. After 
thorough mixing the pH was adjusted to 7.2.
Phagocytosis
Phagocytosis has been measured by the ability of the lymph 
cells to engulf sensitised sheep red blood cells. This 
capacity was studied on cells obtained from thoracic duct 
lymph, peritoneal lavage and splenic macerates.
The method of sensitising sheep red blood cells was as 
follows : -
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Sheep red blood cells were spun in a centrifuge at 
1500 r.p.m. for 5 minutes then resuspended with DAB 
solution. This procedure was repeated three times and 
will subsequently be referred to as a "wash". 0.3 mis 
of the packed washed cells was added to 17.3 mis of 
RPMI 1640 (Gibco Europe, Glasgow) containing 25mM Hepes 
medium and B-Glutamine. 2 mis of 10% foetal calf serum, 
(F.C.S.) 0.2 mis of Penicillin and streptomycin and 
0.2 mis of non essential amino acids were then added and 
finally 50 ;al of rabbit anti-sheep haemolytic serum. 
(Wellcome, Beckenham, Kent) This mixture was incubated 
at 37°C for 30 minutes to allow the ^ globulin of the 
haemolytic serum to coat the sheep cells. The mixture 
was then stored at 4°C and could be used for up to a week.
Phagocytic assay
Cell samples were washed thrice in DAB containing 10%
PCS. To provide the maximum opportunity for phagocytosis, 
intimate cell contact must take place in the presence of 
opsonins. This was achieved by mixing the sensitised cells 
in excess with the effector cells and spinning the mixture 
at 1500 r.p.m. for 5 minutes. The supernatant was then 
discarded and replaced by 1 ml of F.C.S. The cells were 
resuspended and then centrifuged once more. Finally the 
mixtures were incubated at 37^C for 20 and 40 minutes.
After this time the supernatant FCS was discarded and 
replaced by 1 ml of ACT. This lyses all the remaining 
extracytoplasmic red cells during a 5 minute incubation. 
After a further spin the ACT was discarded and the cells 
suspended in 1 ml of DAB/FCS (Cytocentrifuge slides were 
prepared from this solution).
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Estimating the cell count of a sample
Cell suspensions were washed before being counted. On 
resuspending the cells after the third wash they were 
routinely made up to 10 mis with DAB/10% FCS. This 
usually gave a satisfactory working volume and made 
subsequent calculations simple.
Cell counts were made with a haemocytometer (Hawksley 
Crystalite, improved Neubaeur). 0.1 ml of the cell 
suspension was added to 0.9 ml of white cell counting 
fluid (Methylene blue in 2% acetic acid). After mixing 
the cells a drop of this fluid was placed adjacent to the 
cover slip of the haemocytometer. The solution and its 
contained cells became distributed under the cover slip. 
Using the xlO objective of a microscope the number of cells 
within a defined field was counted. This field comprises 
the four outer quadrants marked on the haemocytometer.
The total number of cells within these quadrants was 
counted. This value divided by four and multiplied by 
lO"^  gave the number of cells per ml of the sample
n X  lO"^  = number of cells/ml of sample 
4
This method was used for all cell counts and has been found 
to be reliable and reproducible.
Siliconisinq glassware
It is a characteristic of macrophages that they adhere 
to glass. In order to obtain samples that were not 
depleted of MPS cells by this phenomenon it was necessary 
to coat the glass with a non adherent layer. This was 
achieved by exposing the glassware to an atmosphere of 
dimethyldichlorosilane. The glassware was loaded into 
a large dessicator with a small beaker containing 5 mis
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of dimethyldichlorosilane. After several hours a 
film of silicone coats the glassware. Since the fumes 
are toxic this procedure was carried out in a fume 
cupboard.
Use of the cytocentrifuge
Microscope slide preparations of cell suspensions were 
made using the cytocentrifuge (Cytospin, Shandon 
Southern). The cell suspension was placed in a well 
and when the cytocentrifuge chamber was rotated at high 
speed the suspension was forced onto a microscope slide. 
The cells became randomly distributed on the glass of the 
slide by centrifugal force, but the liquid was taken up 
by absorbent paper placed around the outlet from the well. 
The cell concentration of the suspension was adjusted to 
between 3 and 4 x 10^ cells/ml. Three pipette drops of 
this suspension (100 pi) were introduced into the 
cytocentrifuge well and the cytocentrifuge was run at 
6000 r.p.m. for 5 minutes. This technique was used to 
study cells obtained from thoracic duct lymph, splenic 
macerates and peritoneal exudates.
Slides prepared in this way were allowed to air dry before 
fixation in concentrated formalin vapour for one minute.
Mesenteric lymphadenectomy
The mesenteric lymph nodes in the rat lie in a chain at 
the root of the mesentery. The caecal nodes are found in 
a group at the base of the caecum lying separate from the 
remainder of the mesenteric nodes. To remove the nodes 
the animals were anaesthetised with ether and the abdomens 
shaved. A long midline abdominal incision permitted the 
small intestines to be delivered out of the wound. The
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Lyiriph nodes were removed by first breaking open their 
peritoneal covering with fine sharp pointed forceps then 
dissecting them away from the mesenteric blood vessels.
With care this was easily achieved and minor degrees of 
bleeding stopped quite quickly. Lymph nodes situated 
behind the duodenum were also removed. The duodenum 
was rotated to the left and the nodes were found running 
parallel with the portal vein. Great care was taken in 
the removal of these nodes since a traumatic laceration 
of the portal vein can occur.
After removal of all visible lymphoid tissue the abdomens 
were sutured with a double row of 4/0 black silk and the 
animals allowed to recover. Cannulation of the thoracic 
duct was not performed until at least six weeks had 
passed to allow time for healing. It is unclear whether 
disrupted lacteals can heal or whether new channels open up.
Cannulation of the thoracic duct
Cannulation of the thoracic duct was carried out under ether 
anaesthesia and according to the method of Bollman, Cain 
and Grindlay. (165) Some modifications have been adopted 
and the procedure will be described in full.
After the anterior abdominal wall had been shaved the rat 
was taped to an operating board with the hind limbs fully 
abducted, the upper body rotated to the right and the fore 
limbs taped together on the right. A left subcostal 
incision was made through the skin and muscles of the 
anterior abdominal wall. The intestines and the liver were 
retracted to the right and the left kidney mobilised by 
gentle manipulation using cotton buds. (Johnsons baby 
buds) These structures were then all retracted to the right 
and retained with a gauze swab and a mastoid retractor.
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The abdominal aorta was clearly seen running between 
the crura of the diaphragm. Subsequent dissection was 
performed with a glass rod dissector which was made 
from pyrex glass rods. The rod was heated to melting 
point, then drawn out to fashion a gentle curved tip 
at right angles to the line of the rod. When the 
extreme tip is flamed it becomes bulbous with no sharp 
projections, facilitating atraumatic blunt dissection 
of tissue planes. Using this dissecting rod the fascia 
of the posterior abdominal wall was broken down and the 
aorta fully exposed. At this stage the thoracic duct 
could be seen as a thin, almost transparent line, running 
parallel, slightly behind and to the left of the aorta. 
Dissection just below the crura of the diaphragm allowed 
the rod to be passed around the duct. At this level a 
silk tie was placed to occlude lymphatic return and 
distend the duct. (Plate 1) Further dissection slightly 
lower down allowed a second tie to be placed loosely 
around the distended duct at the level of the superior 
suprarenal artery. With a large hollow needle the posterior 
abdominal wall was pierced just lateral to the vertebral 
bodies. This enabled placement of a length of 800/100/ 
200/100 plastic tubing (Arnold Horwell Ltd., London), 
which was primed with normal saline. This tubing was 
previously heated and moulded into shape. Two curves were 
made. The first was a hair pin bend. The second was a 
slight dorsal angulation in the distal limb. These curves 
allowed the tubing to lie comfortably when the tip was 
within the thoracic duct and the distal limb transfixed 
the posterior abdominal wall. Using fine iris scissors a 
cut was made in the anterior wall of the distended duct.
2-3 mm of the bevelled tip of the cannula was then placed 
within the duct, and this was secured by tying the remaining 
ligature. A second retaining ligature was placed through the 
quadratus lumborum muscle and tied. (Plate 2) The wound was
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then closed after returning the viscerae to their 
normal positions.
The procedure was seen to have been successful when 
lymph entered the tubing and fluid steadily dripped 
from the tip of the tubing.
In order to maintain the animal in a state of full 
hydration a further length of polythene tubing was 
introduced and then tied into the femoral vein and fluid 
infused. This was achieved by a similar method to 
cannulation of the thoracic duct though no curves were 
required in the tubing and finer 800/110/140/100 gauge 
tubing was used. In order to advance the tip of the 
cannula into the inferior vena cava, the limb was fully 
extended and retracted caudally. This makes the line of 
the bifurcation more obtuse and the catheter was less 
likely to be impeded as it was advanced.
The proximal end of this cannula was connected with a 
number 18 gauge Yale microlance needle and through this 
to tubing coming from an electric roller infusion pump.
By this means a constant infusion of 4% Dextrose, 0.18%
NaCl saline containing 1 unit of Heparin per ml was given. 
This minimised the risk of lymph clots forming in the tubing
After placement of these cannulae the rats were confined 
in specially constructed restraining cages. (Plate 3) 
Modifications from the design of Bollman (166) have 
been of a minor nature and will not be described.
A purpose built unit has been designed and built in this 
department. (Plate 4) Each cage has its own tray for 
collecting urine and faeces and this was changed daily.
In addition, as the cages stand on a shelf, this is easily
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cleaned. As can be seen in Plate 4, the infusion 
unit is an integral part of the design and cannulae 
and tubing can be kept neatly.
The following principal problems have been faced with 
this experimental model:
1: Dissection of the thoracic duct as it passes through
the diaphragm can cause a traumatic pneumothorax.
2: Haemorrhage. This can be troublesome during
intravenous infusion of Heparin.
3; Lymph clots within the drainage cannula.
4: Twisting of the cannulae.
5: Dislodgment of the cannulae.
4 and 5 are more likely to happen if the cage is too 
large for the animal. Too much freedom of movement makes 
it almost inevitable that tail movement will cause cannula 
problems.
Once the animals recovered from the anaesthetic they were 
allowed free access to salinised drinking water and normal 
rat pelleted diet. The intravenous infusion rate was 
between 70 and 100 mis in 24 hours. Once lymph drainage 
was fully established output volumes of greater than 200 
mis in 24 hours were commonly achieved.
Non Specific Esterase Stain
This is a diverse group of enzymes whose common link is 
that their substrates are esters of carboxylic acids. The
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Plate 1 : Distension of the 
thoracic duct after placement 
of an occluding ligature.
Plate 2 ; Thoracic duct cannula in situ.
Plate 3 ; The Bollman cage Plate 4 ; The purpose built unit 
allowing 6 parallel drainage 
procedures at any one time.
66
non specific esterases act on simple short chain ester 
substrates like methylbutyrate or naphthyl acetate, 
while the lipases act on higher fatty acids. This 
distinction is not absolute and there is overlap. (167)
The naphthyl acetate method using simultaneous coupling 
to azo dye gives a brilliant colouring reaction but the 
final reaction product is soluble in both alcohol and 
water and hence diffusion artefact is a problem. (167)
In this study the staining method used to identify non 
specific esterase activity employs naphthyl butyrate as 
the substrate. In their report of the use of this technique, 
Crofton, Diesselhoff, den Dulk and Van Furth showed that it 
caused diffuse staining of the cytoplasm of Kupffer cells and 
peritoneal macrophages. (160) They also found a high 
correlation between cytoplasmic esterase staining and other 
macrophage characteristics like phagocytosis, pinocytosis 
and the presence of Fc receptors. MacPherson and Steer have 
shown that this staining method can be applied to the cells 
obtained in the thoracic duct lymph of mesenteric 
lymphadenectomised rats. (164) A positive staining reaction 
was seen in some lymphocytes as one or two dots in the 
cytoplasm. Cells in which diffuse cytoplasmic staining was 
present had the morphological appearance of M.P.S. cells 
both on light and electron microscopy. These cells were 
also glass adherent but showed a gradation of staining and 
variable phagocytic capacities. The method has found to be 
reliable and to give satisfactory results when used to 
stain cytocentrifuge preparations from thoracic duct lymph, 
peritoneal exudates and splenic macerates. It has also 
given good results when used to stain fresh frozen tissue 
sections fixed in formalin vapour.
The substrate solution was made by adding 250 mg of 
napthylbutyrate to 48 mis of dioxan. Pararosaniline 
hydrochloride was made by dissolving IG of pararosaniline in
57
30 mis of twice normal Hydrochloric acid. This was 
hexazotised by adding an equal volume (0.8 ml) of 
sodium nitrite solution (IG sodium nitrite to 30 mis of 
water). 5 mis of 0.4 N Sodium Cacodylate and 0.15 mis 
of Tween 20 were added and the pH of the solution 
adjusted to 6 with further sodium cacodylate. The 
final volume of hexazotised pararosaniline was made up 
to 15 mis with distilled water. 3 mis of methcol were 
added to 2 mis of o< napthylbutyrate substrate solution 
and 15 mis of hexazotised pararosaniline added. Finally 
this solution was made up to 35 mis and the pH again 
adjusted to 5.0. Slides were stained after fixation for 
one minute in concentrated formalin vapour. Between 30 
and 40 minutes was usually required for the staining 
reaction. The slides were then washed with distilled 
water and counter stained with 1 drop of Giemsa for 30 
seconds. Permanent preparations were made by dehydrating 
these specimens through graduated concentrations of 
alcohol, then through xylol and mounting with DPX.
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Chapter 1
Dose level, route and timing of C . Parvum in rats
The splenomegaly induced by C . Parvum is used by the 
manufacturers as a quality control for activity of the 
bacterium. Mice have been used extensively for this 
purpose and 0,35 mg of C. Parvum reliably induces 
splenomegaly. A dose of 4.7 mg has been established as 
the LD^q for female OF^ mice weighing 18-20 g. (169)
Much less is known about the effects of C. Parvum in
other rodents. A literature search failed to reveal
any data of toxicity studies carried out in female Wistar
rats. It was considered to be an essential preliminary
step in this study to establish a dose level which would
produce reticuloendothelial stimulation without unacceptable
toxicity.
Materials and Methods
Intravenous route: C . Parvum was injected intravenously
via the dorsal tail vein. In order to be certain that 
the inoculum was entering the vein it was diluted with 
sterile normal saline to a volume of 1 ml. Successful 
inoculation resulted in free emptying of the syringe. 
Extravasation caused resistance to injection and distension 
of the tail. Dilutions of C. Parvum of 0.035 mg, 0.35 mg, 
0.7 mg, 1.4 mg and 2.8 mg were injected, suspended in 1 ml 
of normal saline. Animals were killed at weekly intervals 
after inoculation and their spleen and body weights 
recorded.
Intraperitoneal route: C. Parvum was injected
intraperitoneally in identical dilutions to those given 
by the intravenous route. Inoculation was performed by
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pinching the shaved anterior abdominal wall and 
introducing the needle at an angle in the midline.
Entry to the abdominal cavity was accompanied by a loss 
of resistance and the ability to move the needle tip 
freely from side to side.
Intralumenal route; 0.7 mg of C. Parvum in 1 ml of 
normal saline was injected into the lumen of the mid small 
bowel or the ascending colon at laparotomy. The 
hypodermic needle was angulated and the inoculum did not 
appear to leak out of the bowel lumen after the needle 
was withdrawn.
Intralacteal route; Cannulation of mesenteric lacteals 
was performed by the supervisor of my research, Mr. H. W. 
Steer. This was achieved using finely drawn capillary 
tubes which were introduced into the lumen of the lacteal 
under visual control using an operating binocular 
microscope. A very much smaller volume was introduced by 
this route and in each case 0.7 mg of C. Parvum was given 
in 0.1 ml of thiomersal.
Results
Immediate
Intravenous : No acute side effects were noted when doses 
of 0.7 mg or less were used. Above this level the animals 
showed marked pilo-erection which passed off within 2 hours 
Shivering and hyperventilation were not noted. Doses even 
as high as 3.5 mg caused only transient side effects and 
no mortality.
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Intraperitoneal; No immediate side effects resulted 
from the intraperitoneal injection of C. Parvum. In 
the group of rats which had undergone prior mesenteric 
lymphadenectomy, treatment, particularly in the higher 
doses, was responsible for some long term morbidity. A 
number of these rats developed inflammatory adhesions 
and localised abscess formation. This made subsequent 
procedures on these animals difficult.
Intralumenal: No acute side effects resulted from this
procedure.
Intralacteal: As the small volume of undiluted C. Parvum
reached the draining lymph node, it was seen to distend 
and blanch. This node was subsequently found to be 
enlarged and to contain large granulomata with considerable 
obliteration of normal nodal architecture. That this effect 
was not simply due to distension of the node has been 
shown by control experiments when 0.1 ml of 0.01% thiomersal 
alone was injected into the node. These results are more 
fully discussed in Chapter 5.
Splenomegaly
The weight of the normal rat spleen increases with the body 
weight of the animal in a linear fashion (Table 1). Any 
observation on splenic size must therefore take into account 
the weight of the animal. In order to standardise animal 
and spleen weights the following calculation has been 
made
Standard spleen weight _ 100 x spleen weight (grams)
(grams) -------------------
Rat weight (grams)
C. Parvum given by both the I.V. and the I.P. routes 
reliably produced splenomegaly in doses of 0.7 mg and more
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(Table 2). 0.35 mg also produced splenomegaly when
given by either route but not in all cases. At each 
dose level the resulting splenomegaly was greater when 
the intravenous route was used. A dose of 0.035 mg did 
not produce any change in spleen weight.
Splenomegaly after I.V. C. Parvum in a dose of 0.7 mg is 
present at 1 week (Table 3), reaches a peak at two weeks 
and then begins to decrease although it is still present 
at four weeks after the injection.
The splenomegaly resulting from 0.7 mg of C. Parvum given 
by a variety of routes is shown in Table 4. All the results 
given on this table are within the first two weeks of the 
injection. Intralacteal C. Parvum induced splenomegaly 
of a similar magnitude to the I.V. route. Intralumenal 
C. Parvum did not cause splenomegaly. Spleen weights were 
measured in 12 rats which had received I.V. C. Parvum 
followed by thoracic duct lymph drainage for 5 days. These 
rats were seriously deficient in lymphocytes at the end of 
this procedure as measured by lymphocyte counts in thoracic 
duct lymph and blood. Despite this, significant splenomegaly 
was still present.
Discussion
A dose of 0.7 mg of C. Parvum given either I.V. or I.P. 
results in marked splenomegaly with little toxicity in 
female Wistar rats. When this bacterium has been used in 
clinical trials systemic doses of 5 to 15 mg have usually 
been given. Side effects of considerable severity result 
from the treatment in humans. If it is assumed that the 
rats weighed 250 grams and the humans weighed 70 kilograms 
then the rat dose of 2.8 mg/kg can be compared with the 
human dose of 0.14 mg/kg. It is remarkable that the rat
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dose, which is 20 times the human equivalent dose causes 
so few side effects. Splenomegaly has not been reported 
following the use of C. Parvum in humans.
When C. Parvum is inoculated into the lumen of the large 
and small bowel no effect on spleen size results. This 
is similar to the effect of subcutaneous administration 
and implies that the bacterium is not absorbed by the gut 
mucosa. When C. Parvum is injected directly into the 
mesenteric lacteals however, marked splenic enlargement 
occurs. C. Parvum, or an active subfraction, appears 
capable of exerting a systemic effect when given in this 
way. The destruction of lymph node architecture resulting 
from intralacteal C. Parvum may permit its entry into the 
general circulation.
Splenomegaly after systemic C. Parvum remains after 
thoracic duct lymph depletion. This implies that the 
cells contributing to the increase in spleen mass are not 
re-circulating lymphocytes.
As a result of the work described in this section a dose 
of 0.7 mg of C. Parvum was selected as being an appropriate 
level for subsequent studies. It was decided to concentrate 
on the I.V. route since this gives marginally greater 
stimulation than the I.P. route with no risk of subsequent 
adhesions or abscess formation. This was of particular 
importance in previously lymphadenectomised rats where it 
was proposed to perform cannulation of the thoracic duct.
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Fig. 1, 1
The Relationship of Splenic Weight to Body Weight 
in Female Wistar 'RatS'
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Time course of C, Parvum induced splenomegaly
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Chapter 2
The effect- of systemic C . Parvum. on the effluent lymph 
cells of the qastro intestinal tract_________________
A series of experiments have been carried out which were 
designed to study the effects of systemically 
administered C. Parvum on the cell composition of the 
thoracic duct lymph in rats. Mesenteric lymphadenectomy 
was performed in these rats at least six weeks prior 
to these studies. The principle aim of this work was to 
establish whether C. Parvum has any influence on gut 
associated M.P.S. cells.
Normal values were obtained after collecting thoracic 
duct lymph from nine rats which had previously undergone 
mesenteric lymphadenectomy, but had received no other 
treatment. C. Parvum was injected in a dose of 0.7 mg 
in 1 ml of normal saline intravenously via the dorsal 
tail vein. Four groups of rats underwent thoracic duct 
and femoral vein cannulation at weekly intervals from 
one to four weeks after the injection. A further group 
of rats received the same dose of C. Parvum intraperitoneally 
and underwent cannulation one or two weeks later. Finally 
a group of rats underwent cannulation and once drainage of 
lymph was established at 48 hours, received 0.7 mg C. Parvum 
via the femoral vein cannula.
Five consecutive overnight collections of lymph were made 
after cannulation of the thoracic duct. Lymph was allowed 
to drain into siliconised glass flasks, standing on 
melting ice within polystyrene boxes. 5 mis of DAB 
containing 20 international units of Heparin/ml were added 
to the flasks prior to the collection. These precautions 
minimised the risk of clots forming in the collected lymph. 
Samples containing more than trivial blood or lymph clots
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were discarded and that days results excluded from 
the analysis. After washing each satisfactory sample 
thrice an estimate of the total cell count was made 
using the haemocytometer. This figure taken with 
the total hours of lymph drainage is used to estimate 
the hourly output of cells from the thoracic duct 
fistula. A cytocentrifuge preparation was made and 
stained for non specific esterase activity. From 
the percentage of cells showing a positive staining 
reaction on the slide the hourly output of these cells
was estimated. A portion of the cell sample was
assessed for the ability to phagocytose sensitised 
sheep red blood cells. Cytocentrifuge preparations 
made after this assay permitted an estimate of the 
percentage and number of phagocytic cells draining 
hourly.
The statistical significance of the results in this and 
the following chapter has been carried out by comparing 
the variance of the regression lines. A Hewlett 
Packard Model 10 calculator was programmed to plot the 
regression line from the daily mean values. The 
regression line is allocated the value B and its
Variance Var B. The t value for the significance of
the observation is then calculated using the equation:-
t = B. - B,
vVar "t Var
B. B,
when B^ represents the 
normal value and the 
value from treated rats
Results
The effect of C. Parvum on the hourly cell output in thoracic 
duct lymph is shown in table 2.1 and figure 2.1.
Over 97% of the cells in the thoracic duct lymph of
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rats which have undergone mesenteric lymphadenectomy are 
lymphocytes. The figure shows that rats quickly became 
depleted of these cells during the chronic drainage of 
lymph. Rats which had received systemic C. Parvum had 
been injected between one and four weeks prior to 
cannulation. The third group of results shown in figure 
2.1 are from rats which were injected with C. Parvum on 
the second day after the drainage of lymph had been 
established. C. Parvum given either prior to thoracic 
duct cannulation or during the drainage of lymph had no 
effect on the numbers of effluent cells.
The percentage of the total cell output having a positive 
staining reaction for non specific esterase is shown in 
Table 2.2 and figures 2.2 to 2.6, In the figures the mean 
percentage of these cells with the standard error of their 
means, have been plotted. For diagramatic convenience 
the standard error of the mean has been shown as its 
positive or negative value throughout this work. In each 
figure the normal results have been compared with those 
from rats at varying time intervals after the injection 
of C. Parvum. In all animals the percentage of esterase 
positive cells in thoracic duct lymph rose over the five 
day drainage period. The highest percentage found was 
just over 3% on days four and five of drainage in the 
rats which had been injected with 0.7 mg of C. Parvum two 
weeks previously. Comparison of the regression lines 
obtained by plotting the values from normal and C. Parvum 
treated rats showed that treatment had no influence on 
the percentage of esterase positive cells in thoracic duct 
lymph. Wilcoxons rank sum test for unpaired samples was 
used to compare some individual results which appeared 
to differ from those from normal rats, for example the 
values obtained on days 4 and 5 three weeks after I.V.
C, Parvum (fig 2.4), The differences were not statistically 
significant.
The effect of systemic C. Parvum on the number of esterase 
positive cells in thoracic duct lymph is shown in Table 2.3
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and figures 2.7 to 2.11. Although, as has been shown, 
the percentage of esterase positive cells rose over the 
five days of drainage, the absolute number slowly 
decreased. Comparison of the regression lines shows 
that C. Parvum treatment had no effect on the numbers 
of esterase positive cells in thoracic duct lymph in 
all of the groups studied except four weeks after I.V.
C. Parvum. In this group there was a statistically 
significant increase (P<0.01).
The hourly output of phagocytic cells is shown on 
tables 2.4 and 2.5 and figures 2.12 to 2.17, In the figures 
the results from the first and second weeks after C. Parvum 
have been combined for reasons of brevity, as have those 
from the third and fourth weeks after injection. C. Parvum 
treatment had no influence on the output of phagocytic 
cells in the thoracic duct lymph of mesenteric 
lymphadenectomised, but otherwise normal, rats. There 
were no marked differences noted between the number of 
phagocytic cells found after 20 or 40 minute incubation 
periods.
C. Parvum given intravenously in a dose of 0.7 mg after 
two days of drainage of thoracic duct lymph caused no acute 
alterations in the output of esterase positive or phagocytic 
cells. (Table 2.6) In this small group of animals 
drainage was slow to become established and the cell output 
was low for the first 48 hours. After the injection of 
C. Parvum the values obtained closely corresponded with 
those from normal animals.
Discussion
Complete surgical removal of the mesenteric lymph nodes 
in rats permits the collection of gut associated M.P.S. 
cells. Cells obtained by this method belong to two
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broad classes. Firstly there is a population of cells 
which are the same size as medium to large lymphocytes.
These adhere strongly to glass, are phagocytic and have 
a small amount of cytoplasm with a lobulated nucleus.
The second cell population is of larger cells which are 
not strongly glass adherent, and are less capable of 
phagocytosis. They have abundant cytoplasm with "frilly" 
processes like pseudopodia. A capacity for metabolic 
activity is indicated by the numerous intracytoplasmic 
organelles seen with the electron microscope. While 
these larger cells stain diffusely and often densely for 
non specific esterase the smaller phagocytes either stain 
poorly or not at all. (164) (Plate 1, Pagel45) Direct 
cannulation of the lacteals in rats which have not 
undergone mesenteric lymphadenectomy permits the collection 
of cells similar to those found in the thoracic duct 
lymph after lymphadenectomy. (164) Lacteal lymph, however, 
has a higher percentage of M.P.S. cells than thoracic 
duct lymph. This may be due to dilution of thoracic duct 
lymph for example by the influx of hind limb lymph.
Afferent lymph carries a variable population of cells 
which belong to the M.P.S. This is not the case in 
efferent lymph which has passed through lymph nodes.
Whether they are destroyed or transformed during transit 
through the node is unclear. Labelled M.P.S. cells in the 
afferent lymph become distributed throughout the thymus 
dependent paracortical area. They are not found in the 
primary follicles, medullary cords or germinal centres and 
have a completely different distribution from labelled 
lymphocytes or infused inert particles. (122)
The proportion of cells in thoracic duct lymph capable 
of phagocytosis varies with the method of study. (164) 
Values obtained using latex particles are higher than 
when using antibody coated red blood cells. Sensitised
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sheep red blood cells have been used in this study because 
of the east with which they are recognised on light 
microscopy. Small particulate material can easily be 
mistaken for ingested latex but the appearance of intra 
cytoplasmic red cells in unlikely to lead to error. The 
present finding that cells which ingest sensitised sheep 
red blood cells usually display very little reaction 
with non specific esterase stains is in accordance with 
the report from MacPherson and Steer. This is not always 
the case and plate 2 (Page 145) shows a cell that is quite 
densely esterase stained yet contains three ingested red 
blood cells. Although phagocytosis was studied after two 
different incubation times the number of cells which 
showed this capacity remained the same. It is unlikely 
that limiting the incubation period to 20 minutes would 
be satisfactory for future work.
Cells staining for non specific esterase are present 
throughout the period of drainage, the percentage varying 
from 0.5 to 3%, Although the percentage of these cells 
rises over the five day drainage procedure the absolute 
count falls slowly as the total cell output falls. This 
was the case in all the groups studied and at no time 
after C. Parvum treatment was the percentage of esterase 
positive cells significantly altered.. Nor did C. Parvum 
alter the number of esterase positive cells in thoracic 
duct lymph except in one group of animals. Whether the 
increase found four weeks after I.V. C. Parvum represents 
a true stimulation is not clear. No animals were cannulated 
later than this period since the other signs of reticulo­
endothelial stimulation (splenomegaly and bone marrow cell 
cultures) are returning to normal by four weeks. (19)
The number of phagocytic cells in thoracic duct lymph 
is not influenced by C. Parvum treatment. This is in 
contrast to the observations that C. Parvum increased
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clearance of colloidal carbon, (2) and radiolabelled 
albumin. (22) Augmented clearance of these particles 
may be solely due to increased uptake by fixed tissue 
phagocytes, for example in the liver and spleen.
The total cell output in thoracic duct lymph is not 
influenced by C. Parvum treatment. C. Parvum given 
intravenously causes an acute fall in blood lymphocyte 
numbers within 24 hours of injection. (23, 25, 99,
Chapter 4) It is of interest that cells in the thoracic 
duct, which are 97% recirculating lymphocytes, are not 
affected by C. Parvum. The observations of Gowans and 
Knight (154) showed that these cells are mainly small T 
lymphocytes that continually recirculate from the blood 
to the lymph by crossing the walls of the post capillary 
venules of the lymph nodes. These lymphocytes re-enter 
the blood when the thoracic duct lymph passes into the 
subclavian vein. It is not clear whether the acute 
lymphocytopaenia in the blood after C . Parvum treatment is 
due to the suppression of another group of lymphocytes.
In a group of five rats C. Parvum was injected after two 
days of lymph drainage. No immediate alterations resulted 
in the lymphocyte output in thoracic duct lymph. Nor did
C. Parvum given previously either intravenously or 
intraperitoneally have any effect on the thoracic duct 
lymphocyte output.
Conclusions
Systemic C. Parvum has no influence on:-
1. the output of thoracic duct lymphocytes
2. the percentage of esterase positive cells in 
thoracic duct lymph
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the number of esterase positive cells in 
thoracic duct lymph up to three weeks after 
treatment. The number of esterase positive 
cells in thoracic duct lymph four weeks 
after I.V. C. Parvum was increased.
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TABLE 2.1
HOURLY OUTPUT OF CELLS IN THORACIC DUCT LYMPH
Normal Rats 1 2 3 4 5 Days
n 9 9 9 7 4
X 13.4 8.7 4.6 4.8 2.1 x 10®
+8EM 8.7 2.7 1.8 2 0.7 x 10®
After C. Parvum 1 2  3 4 5 Days
0.7 mg IV
n 28 26 28 28 25
X 17.3 14.9 8.7 5.6 1.9 x 10®
SEM 11.4 8.9 4.5 3.2 0.9 x 10
C. Parvum 1 2 3 4 5 Days
on day two
of drainage n 5 5 5 5 5
X 10.3 7.7 6.5 6 2.7 x 10®
SEM 8.. 7 4.3 0.9 2.7 1.5 x 10
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Table 2.2 Percentage esterase positive cells
in thoracic duct lymph
Day
C. Parvum 0.7 mg 
IV X one week 
prior to 
cannulation
C. Parvum 0.7 mg 
IV X two weeks 
prior to 
cannulation
C. Parvum 0.7 mg 
IV X three weeks 
prior to 
cannulation
C. Parvum 0.7 mg 
IV X four weeks 
prior to 
cannulation
C. Parvum 0.7 mg 
IP X two weeks 
prior to 
cannulation
n 9 12 12 10 4
X 1.27 1.4 1.85 1.82 2.2
SEM 0.23 0.14 0.29 0.23 0.45
n 8 7 7 7 7
X 0.9 1 1.76 1.76 2.07
SEM 0.09 0.15 0.17 0.17 0.17
n 7 6 8 6 4
X 1 1.7 2.01 2.01 3.03
SEM 0.23 0.38 0.38 0.29 0.86
n 6 8 9 8 6
X 0.96 1.27 2,3 3.13 3.18
SEM 0.29 0.29 0.48 0.52 0.76
n . 9 9 9 9 7
X 1.02 1.6 1.5 2.4 2.97
'SEM 0.14 0.21 0.24 0.3 0.45
n 8 7 6 6 6
X 1.2 1.5 2.1 1.97 2.1
SEM 0.16 0.23 0.27 0.19 0.42
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Figure 2.2
Percentage of esterase + ye cells in thoracic duct Ijoiiph.
^ One week after C. Paryum 
0.7 mg IV 
• Normal
2 .
1 .
0.31
Var B. = 0.00138
Var B 0.00363
Days
Figure 2.3
Percentage of esterase + ve cells in thoracic duct lymph
2.5
1.5
%
* Two weeks after C. Parvum 
0.7 mg IV
• Normal
Var B, ;= 0.00138
Var B„ = 0.00763
Days
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Figure 2.4
Percentage of esterase + ye cells in thoracic duct lymph
2.5
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* Three weeks after C. P&ryum 
0.7 mg ly ^
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Figure 2,5
Percentage of esterase + ve cells in thoracic duct lymph
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0.7 mg IV
• Normal
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Figure 2.6
Percentage of esterase + ve cells in t&oracic duct lymph
* Two weeks after C. Parvum
Normal
2 .
2
1 .
0.23
0.21
Var = 0.00138
1
Var B 0.00528
Days
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TABLE 2.3
Number of esterase 
Hourly cell output
positive cells in
X  1 0
thoracic duct lymph
Day 1 2 3 4 5
No prior C. Parvum n g 1 1 1 1 9 9
X 15.9 15.2 8.7 8.4 4.5
^SEM 3.2 2.3 1 . 1 1.3 0.9
C. Parvum 0.7 mg 
IV :s one week
n 8 7 7 8 7
prior to 
cannulation
X 13.8 17.9 13 .5 1 0 . 8 3,1
SEM 3.2 5. 5 8.4 3.5 0.6
C. Parvum 0.7 mg 
IV X  two weeks
n 7 7 7 6 4
prior to 
cannulation
X 9.2 25.5 16.5 11.3 5.3
^SEM 2.03 6.9 4.6 3.2 1 . 8
C. Parvum 0.7 mg 
TV X three weeks
n 7 7 9 8 5
prior to 
cannulation
X 15.3 1 2 . 6 15.5 1 1 3.8
*SEM 4.6 3.5 3,6 2 . 2 0.7
C. Parvum 0.7 mg 
IV X  four weeks
n 9 8 9 9 6
prior to 
cannulation
X 19.2 28.6 13.8 15.1 1 0 . 1
4.1 7.0 3.6 3.3 5.8
C. Parvum 0.7 mg 
IP X two weeks
n 1 0 9 9 9 8
prior to 
cannulation
X 15,9 13.2 7,5 5.5 5.8
*8EM 2 . 2 2.9 1 . 6 1 . 1 1 . 1
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figure 2.8
Number of esterase + ve cells in thoracic duct lymph
25 n
20 -
15-
10-
5-
X 10 cells/hour
Hs One week after C. Parvum 
0.7 mg IV 
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Figure 2.9
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Pigure 2.10
Number of esterase + ve cells in thoracic duct lymph
25 X 10 cells/hour * Three weeks after C. Parvum 
0.7 mg IV
• Normal
20
Var B 0.24215
Var B„ = 1.019
10
Days
Figure 2.11 Number of esterase +ve cells in thoracic 
duct lymph
* Four weeks after C. Parvum 
0.7 mg rv
• Normal
25 X  10
-2.9620
-3.17
Var B 0.242
3 .32Var B15
0.01
10
Days
1 32 4 5
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TABLE 2.4
Numbers of phagocytic cells in thoracic duct lymph 
Hourly cell output x 10
Day 1 2 3 4 5
No prior C. Parvum
20 minute incubation n 9 9 9 5 3
X 4.5 3.0 1.2 1.5 0.4
^SEM 0.93 0.8 0.3 0.86 0.05
40 minute incubation n 9 9 9 5 3
X 3.5 3.6 1.8 1.8 0.4
^SEM 0.7 0.6 0.6 0.6 0.02
C. Parvum 0.7 mg IV 
one and two weeks 
previously
20 minute incubation n 10 8 11 11 9
X 4.1 3.3 2.1 1.53 0.9
^SEM 1.3 1.2 0.59 0.5 0.37
40 minute incubation n 10 9 11 11 9
'X 3.79 2.8 2.87 1.6 0.88
■^ SEM 1.1 1.23 1.1 0.54 0.42
94
TABLE 2.5
Day 1 2 3 4 5
C. Parvum 0.7 mg IV 
three and four weeks 
previously
20 minute incubation n 16 16 17 17 11
X 1.88 2.72 2.26 1.62 0.4
^SEM 0.6 0.89 0.5 0.39 0.11
40 minute incubation n 15 16 18 17 10
X 4.8 2.69 2.23 1.59 0.53
'*'SEM 1.1 0.75 0.5 0.37 0.14
C. Parvum 0.7 mg IP 
two weeks previously
20 minute incubation n 10 9 10 7 4
X 3.9 1.8 1.4 0.6 0.6
^SEM 1.4 0.6 0.4 0.2 0.35
40 minute incubation n 9 9 10 8 4
X  3.7 2.8 1.9 0.9 0.8
*SEM 0.8 1.3 0.5 0.3 0.25
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No. of phagocytic cells on a 20 minute incubation 
1 and 2 weeks after C. Parvum 0.7 mg I.V.
X cells/hourX 10
* One and two weeks after C. Parvum
• Normal
0.82
0.0406Var B.
0.00403Var B
Days
Figure 2.13
No. of phagocytic cells on a 40 minute incubation 
1 and 2 weeks after C. Parvum 0.7 mg I.V.
X 10_ cells/hour
*One and two weeks after C. Parvum 
• Normal
- 0.8
-0.7
0.0269Var B
Var B 0.0111
Days
uigure %.14
No.' of phagocytic cells on a 20 minute incubation 
3 and 4 weeks after C. Parvum 0.7 mg I.V,
yb
X 10 cells/hour
* Three and four weeks after C. Parvum
• Normal
-0.97
0.406
Var a = 0.0406
0.0468
Days
1 42 3 5
Figure 2.15
No. of phagocytic cells on a 40 minute incubation 
3 and 4 weeks after C, Parvum 0.7 mg I.V.
X 10 cells/hour
* Three and four weeks after C. Parvum
• Normal
- 0.8
Eg = -0.96 
Var = 0.0269 
yar B = 0.0242
Days
1 2 3 4 5
jigure a.xb 97
No. of phagocytic cells on a 20 minute 
incubation after C, Parvum 0.7 mg I.P.
X 10
*C. Parvum I.P. 
• Normal
-0.97
-0.78
Var 0.0406
Var 0.0422
Days
Figure 2.17
No. of phagocytic cells on a 40 minute 
incubation after C. Parvum 0.7 mg I.P.
X 10 cells/hour
* C . Parvum I.P.
• Normal
—0.8
-0.77
Var B. 0.0269
Var B 0.0086
Days
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TABLE 2.6
The effect of 0.7 mg C. Parvum given 
drainage of thoracic duct lymph
I.V. after two days
Day 1 2 3 4 5
Percentage of 
esterase positive
n 5 5 5 5 5
cells X 0.6 1.1 1.2 1.4 2.3
^SEM 0.13 0.22 0.4 0.3 0.5f
Number of esterase 
positive cells hourly
n 5 .5 5 5 5
output % 10 X 6.5 7.7 8.2 9.3 5.3
^SEM 2.9 1.8 3.26 4.2 1.8
Number of phagocytic 
cells after 20 minute
n 5 5 5 5 5
incubation  ^
Hourly output x 10
X 3.4 2.7 2.5 2.2 0.9
^SEM 1.1 2.8 1.2 1.4 0.5
Number of phagocytic 
cells after 40 minute
n 5 5 5 5 5
incubation  ^
Hourly output x 10
X 3.4 2.7 1.7 4.3 1.0
■^ SEM 1.1 1.1 0.4 3.0 0.9
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Chapter 3
The. eff ect, of .systemic. .0. ^ Parvum on cells in. the thoracic 
duct lymph of rats bearing colonic cancers.______________
Thoracic duct cannulation has been carried out in nine 
mesenteric lymphadenectomised rats bearing small 
dimethyIhydrazine (D.M.H.) induced colonic cancers. The 
mesenteric lymph nodes were removed before beginning tumour 
induction. The numbers of esterase positive and phagocytic 
cells draining hourly were calculated using the method 
described in Chapter 2. A further group of six tumour 
bearing mesenteric lymphadenectomised rats were injected 
with 0.7 mg of C. Parvum intravenously between 7 and 14 
days before undergoing cannulation of the thoracic duct.
D.M.H. (Sigma Chemicals, Poole) was injected subcutaneously 
once weekly in a dose of 30 mg/kg body weight for fifteen 
weeks. Crystalline D.M.H. was refrigerated until use. A 
suspension of the carcinogen was prepared by adding 0.35 g 
of D.M.H. to 100 mis 0.9 N saline and 1.5 g ethylenediamine 
tetracetic acid. The pH of the solution was adjusted to 
5.5 with 0.1 M sodium hydroxide. Since D.M.H. is a potent 
carcinogen this procedure was carried out wearing gloves 
and a face mask and the chemicals were decanted and mixed 
inside a fume cupboard. This minimised the risks of 
absorption of D.M.H. through the skin or mucous membranes.
Rats were injected weekly with 2 mis of freshly prepared 
solution. As most of the rats being used weighed between 
200 and 250G the dose of 7 mg was equivalent to 30 mg/kg 
body weight. The total accumulated dose was 450 mg/kg.
During tumour induction the rats were housed in cages with 
metal grid floors. Faeces and urine passed through the grid 
to a collecting tray. Technicians cleaning the collecting 
tray were advised to wear gloves. The cages were kept in 
a separate area of the animal house and marked with carcinogen
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precaution notices. After finishing the series of D.M.H. 
injections the animals were closely monitored for signs 
of tumour development, for example, weight loss and bloody 
diarrhoea. As the tumour bearing animals were to undergo 
cannulation of the thoracic duct it was important that 
they be in as good a physical condition as possible. Random 
laparotomies were performed from 30 weeks after the 
beginning of tumour induction. When small tumours were 
found, other rats from the same group underwent thoracic 
duct cannulation. The presence of large bowel tumours 
was confirmed in each of these rats at the end of the 
experiment when, after killing the rat, the whole of the 
large bowel was removed and examined.
Results
The percentage and number of esterase positive cells in 
the effluent lymph of tumour bearing rats did not differ 
significantly from normal rat values. (Table 3.1, figs. 3.1 
& 3.3) Nor did the systemic administration of C. Parvum 
in a dose of 0.7 mg between seven and fourteen days before 
cannulation have any effect on these results. (Table 3.2, 
figs. 3.2 & 3.4)
There was a significant depression in the numbers of 
phagocytic cells in the thoracic duct lymph of all of the 
tumour bearing rats whether or not C. Parvum had been given. 
(Table 3.1 & 3.2, figs 3.5 - 3.8) There was no difference 
in the degree of suppression between the two groups of 
tumour bearing rats. C. Parvum did not influence the 
output of esterase positive or phagocytic cells in thoracic 
duct lymph. The phagocytic cells found in the thoracic 
duct lymph of those rats bearing tumours were similar in 
appearance to those from normal lymphadenectomised rats. 
Other phagocytic cells like polymorphonuclear leukocytes 
were not seen. As has been stated, it was aimed to find
101
developing tumours early before the rats become unfit 
to undergo the cannulation experiment. In these 
animals the tumours were confined to the large bowel.
(Plates 3, 4 Page 145) Prior extirpation of the 
mesenteric lymph nodes did not appear to facilitate 
early metastatic spread of cancer. Malignant cells were 
not identified in the thoracic duct lymph. In a separate 
series of D.M.H. tumour inductions three male DA rats 
and one female Wistar rat developed squamous carcinomas 
of the middle ear.
Discussion
C . Parvum has been reported to increase the phagocytic 
uptake of colloidal carbon (2),, latex particles (87) 
and sensitised red blood cells (168) (12). Thomson and 
his co-workers reported that Fc receptor bearing cells 
within tumours are increased by C. Parvum treatment, (9) 
but found that there was no clear effect on cells capable 
of phagocytosing carbon. It is uncertain if M.P.S. cells 
capable of exerting an anti tumour action are in fact 
phagocytic. Phagocytosis is a characteristic of mature 
macrophages, which would not be increased in numbers of 
functional capacity in the first two weeks after C. Parvum 
treatment. (168) Studies on peritoneal exudate cells 
suggest that anti tumour activity is exerted by the largest 
cells present, while immune responsiveness is dependent on 
medium sized and small cells. (89)
The observation that the number of phagocytes in efferent 
gut lymph is suppressed in rats suffering from colonic 
cancer is of considerable interest. It seems unlikely 
that this is directly due to toxic depression caused by the 
carcinogen since the last dose of D.M.H. was at least 10 
weeks prior to the cannulation experiment. Although the half 
life of D.M.H. in the circulation is unknown, it seems unlikely 
that a chemical suppression would be selective for an 
individual type of cell. Nor do the low levels of phagocytes 
appear to facilitate metastatic spread since this tumour 
rarely metastasises. (74) C. Parvum
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given between one and two weeks prior to the cannulation 
procedure had no influence on the suppressed levels of 
phagocytes. It is not clear from these experiments whether
C . Parvum given longer before cannulation would have 
affected the phagocytic cells. However, in Chapter 2 it 
was shown that even four weeks after C. Parvum there were 
no alterations in phagocytic cells. It does not seem 
likely that C. Parvum exerts an effect on the numbers of 
these cells present in thoracic duct lymph.
Mice and rats bearing transplantable tumours show increased 
rates of clearance of carbon particles from the blood.
(169) This is not universally found and using the 
Lewis lung carcinoma model Otu reported depression of 
carbon clearance shortly after tumour transplant. (147)
He also noted suppression of macrophage locomotion and 
bone marrow macrophage colony formation.
Increased phagocytosis has been reported in studies on
peritoneal exudate cells (PEC) of mice bearing transplanted
tumours. In mice bearing recently transplanted
methylcholanthrene induced fibrosarcomas in their footpads
51PEC showed increased phagocytosis of Cr labelled sheep 
red blood cells coated with IgG. (170) In another report
PEC from mice receiving an inoculum of sarcoma - 180 
showed increased uptake of staphylococcus aureus. (171)
These workers have also identified a serum factor which 
blocked this enhancement of phagocytosis. Other phagocytosis 
inhibiting factors have been identified. Serum from cancer 
patients and tumour bearing animals can inhibit the lipid 
ingesting capacity of macrophages. (172) Nematode 
activated macrophages show enhanced in vitro phagocytosis 
of Walker carcinosarcoma cells. (173) This enhancement is 
abrogated by adding serum from the same rats to the 
incubation. The blocking factor in this case belongs to the
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IgG 2 subclass of immunoglobulins. This group of 
immunoglobulins has also been found to prevent the 
attachment and phagocytosis by macrophages of leukaemia 
cells both in vitro and in vivo (174). It may be that 
tumours have different capacities to stimulate the 
development of blocking factors. Whether any such 
factors were present in the serum or lymph in the rats 
in this series is unknown.
CH^ - N H. H Cl 
CH3 - N H. H Cl
1, 2 Dimethy1-hydrazine Dihydrochloride (D.M.H.)
D.M.H. is one of several related hydrazine derivatives 
which induce intestinal tumours in laboratory animals.
1, 1 DimethyIhydrazine and methylhydrazine are both 
naturally occurring substances. The former is found in 
cigarette smoke and the latter in edible fungi. Both 
are used in space rocket propellants. (175) D.M.H. 
itself has not been identified as a naturally occurring 
substance.
When D.M.H. is injected subcutaneously into a wide variety 
of rodents in a dose of between 20 mg/kg and 40 mg/kg 
weekly a high proportion develop tumours of the large and 
small bowel. (176) This dose level causes transient 
hepatotoxicity but no acute deaths. Most workers have 
given a total dose of less than 400 mg/kg body weight 
injected weekly in 10 to 15 equal doses. (176, 177, 178, 
179)
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Small areas of dysplasia begin appearing in the colon 
after the 12th week of tumour induction. (177) From 
the 19th week onwards frank carcinomas begin to appear 
either as plaques or sessile polyps. All grades of 
mucosal change can be recognised from dysplasia to 
carcinoma in situ and finally invasive carcinoma. At 
a later stage similar adenocarcinomata may appear in the 
small bowel. Alteration in goblet cell mucin can be 
demonstrated by special stains as early as 7 weeks after 
tumour induction has commenced. High iron diamine-aleian 
blue stains enable a distinction to be made between 
sialomucins and sulphomucins. (180) As epithelial
dysplasia increases sialomucins begin to predominate and 
this is accompanied by a decrease in sulphated material, 
similar changes have been demonstrated in the human large 
gut not only in apparently normal mucosa adjacent to 
colorectal cancers, but also at distant sites. These 
changes may precede the appearance of the more classical 
histological features of malignancy.
Mechanism of Carcinogenesis - Precisely how D.M.H. induces 
adenocarcinoma of the bowel is not known. Alteration of 
cellular differentiation could be mediated by interaction 
with nucleic acids or protein. (177) Changes are 
described in the nucleic acid metabolism and proliferative 
capacity of the colonic epithelium in D.M.H. treated mice, 
(181) which are similar to those found in human colonic 
mucosa adjacent to carcinoma and neoplastic polyps.
Some evidence suggests that D.M.H. is metabolised to a 
more active carcinogen in the liver. (178) Although only 
small amounts of radiolabellçd D.M.H. appears in the bile 
the effects of chronic intoxication with the drug have not 
been studied. Histological signs of acute hepatic toxicity 
result from use of D.M.H.
105
Dietary factors - The low incidence of colonic cancer 
in native Africans has been attributed to their high 
fibre diet. While epidemiologists continue their debate, 
a controlled clinical trial would obviously be impossible 
in humans. CruSe has studied the effects of the 
alteration of dietary fibre intake in rats undergoing 
tumour induction with weekly D.M.H. (182)
Wistar rats were divided into three groups. All were 
inoculated with subcutaneous D.M.H. 40 mg/kg weekly 
for 13 weeks. The groups were fed on diets containing 20% 
w/w fibre (high fibre), 4.8% w/w fibre (normal laboratory 
diet and 0% w/w fibre respectively. No significant 
alterations in the rats of tumour induction or survival 
resulted.
In contrast to this work,rats undergoing similar tumour 
induction were protected by an all liquid elemental diet. 
(178) In this study rats were divided into two groups, one 
on a normal laboratory diet and the other on the commercial 
low residue diet Vivonex (Eaton laboratories). Each 
received D.M.H. 20 mg/kg weekly by subcutaneous injection. 
Rats fed on normal diets developed extensive tumours by 
week 24 of this regimen. In addition to tumours of the 
large bowel, the small bowel and liver-were frequently 
involved. Several rats in this group did not survive the 
full term of the experiment. In the Vivonex fed group all 
rats survived the full term and developed predominantly 
large bowel tumours.
In the same paper D.M.H. was shown to cause acute 
histological changes in the liver and the Vivonex treated 
group appeared to be protected as these changes were less 
marked. In the present study all rats were allowed free 
access to a standard pelleted rat food and water and 
received 30 mg/kg D.M.H. subcutaneously by weekly injection
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for 15 weeks. It is of interest to compare the differing 
time intervals between beginning a course of injections 
of D.M.H. and the appearance of colonic tumours.
Castleden and Shilkin (178) and Cruse et al (179) used 
the same dosage of D.M.H., 20 mg/kg week, although the 
former workers gave 24 injections and the latter 20, The 
control group of animals in both studies received a normal 
pelleted rat diet and water. In the former study none of 
the rats survived for the full 24 weeks of the experiment 
and at post mortem they all had extensive tumours of the 
large and small bowel. In the report from Cruse, using 
the same strain of rats (Wistar) the control group of rats 
all survived until 36 weeks, although they all had tumours, 
In the present study using a higher weekly dose for a 
shorter period, Wistar rats developed small large bowel 
tumours between 30 and 35 weeks after the beginning of the 
course of injections. There seems to be a considerable 
variation in the time interval required before large bowel 
tumours develop. This may be due to variations in the 
method used to prepare the carcinogen. The method adopted 
in the work described in this chapter was the same as that 
of Cruse et al.
The Immunoqenicity of D.M.H. induced colonic cancer - 
Colorectal cancers induced in rodents by D.M.H. possess 
tumour associated antigens demonstrable by in vitro assays, 
(183) Tissue specific antigens induce cellular immunity 
and humoral antibodies in rats developing primary bowel 
carcinomas, in recipients of isografts of such tumours and 
in animals immunised with irradiated tumour cells. Sera 
from tumour bearing rats block lymphocyte toxicity against 
the tumour cells. (183)
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Rats undergoing D.M.H. tumour induction are partly- 
protected by prior immunisation with D.M.H. induced 
tumours. (184)
A similar, but lesser protective effect is seen by 
immunisation with N-methyl-N-Nitroguanidine induced 
colorectal tumours. Female rats allowed to have a 
number of litters during carcinogenesis were also 
partially protected. These results suggest not only 
the presence of a tumour associated antigen in these 
chemically induced tumours, but that these antigens are 
partially shared, because weak cross immunisation occurs. 
There is also a possible shared antigen with embryonal 
cells although other protective effects of pregnancy 
cannot be discounted.
C. Parvum and D.M.H. : - C . Parvum given four times in a 
dose of 3.5 mg intraperitoneally to rats after week 13 
of D.M.H. tumour induction resulted in a marked acceleration 
in the rate of tumour development. (74) Rats which received 
C. Parvum not only developed early and extensive tumours, 
but also developed métastasés and other malignant tumours, 
particularly of the middle ear. Concern was voiced as to 
the effect of C. Parvum in human colonic cancer on the 
basis of these results.* However, the dose of C. Parvum 
used in this animal study was greatly in excess of the human 
equivalent dose and also far greater than the dose required 
to cause reticuloendothelial stimulation in rats (as manifest 
by splenomegaly). These workers extrapolated from tumour 
inhibition studies in mice where 350 ;ag had been shown 
to result in maximal tumour inhibition. (84) Since the mice 
had weighed 15-20 G a tenfold dose of C. Parvum was 
selected for the rat studies (weight 150-200 G ). This 
logic applied to the use of C. Parvum in humans would call 
for a dose of over 500 mg which is greatly in excess of the 
usual dose of about 10 mg. It is particularly worthy of
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note that these workers had originally intended to 
administer C. Parvum once every three weeks, but found 
that the animals were failing to gain weight after 4 
doses and treatment was stopped. It seems possible that 
this group of rats fared badly as a direct result of the 
toxic action of high doses of C. Parvum. The dose of 
an immune modulator required to enhance the immune 
response is critical. Dose responses are non-linear in 
nature and excessive doses can lead to immunosuppression. 
(185)
Conclusions
1. The non specific esterase positive cell output in 
the thoracic duct lymph is the same in tumour bearing and 
normal mesenteric lymphadenectomised rats.
2. The number of phagocytic cells in the thoracic duct 
lymph of tumour bearing rats is suppressed.
3. C. Parvum treatment has no influence on the output of 
non specific esterase positive cells or phagocytes in the 
thoracic duct lymph of tumour bearing rats.
4. Wistar rats had been shown to have an increased 
susceptibility to D.M.H, tumour induction when pre-treated 
with C. Parvum. (179) The significance of this observation 
is questioned in view of the very high dose levels of
C. Parvum used in the experiment.
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TABLE 3.1
M.P.S, cells in tlxe thoracic duct lymph of rats with colonic tumours
Day
est + ve
Number of est + ve 
X 10 cells/hour
Number of phagocytic cells n 9 
on a 20 minute incubation 
X 10 cells/hour
on a 40 minute incubation 
X 10 cells/hour
n 9 9 9 9 9
X 1.3 2.2 2.7 2.16 2.87
SEM 0.15 0.42 0.28 0.26 0.41
n 9 9 9 9 9
X 18.47 13.98 19.37 9.8 9.78
SEM 2.68 2.45 2.91 1.92 2.3
9 9 9 4
X 0.43 0.12 1.75 0.84 1.68
‘SEM 0.42 0.12 0.41 0.35 0.21
n 9 9 9 9 4
X 0.96 1.13 1.09 0.89 1.55
‘‘SEM 0,63 0.55 0.42 0.38 0.32
TABLE 3.2
The effect of C. Parvum on M.P.S, cells in thoracic duct 
lymph of rats with colonic tumours
C. Paryum injected l.T, 7 - 14 days prior to the experiment
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est + ve
Number of est + ve 
X 10^ cells/hour
Number of phagocytic 
cells on a 20 minute 
incubation 
X 10 cells/hour
Number of phagocytic 
cells on a 40 minute 
incubation 
X 10 cells/hour
Day 1 2 3 4 5
n 5 6 6 6 6
X 1.2 1.78 2.88 2.48 3.31
*8EM 0.25 0.68 0.56 0.42 0.57
n 5 6 6 6 6
X 13.2 12.58 11.8 6.82 3.82
^SEM 2.64 5.18 1.68 1.20 0.9
n 5 6 6 6 6
X 1.2 0.9 0.5 0.3 0.27
^SEM 1.2 0.58 0.31 0.19 0.09
n 5 . 6 6 6 6
X 2.34 0.88 0.38 0.17 0.25
^SEM 0.97 0.57 0.26 0.17 0,09
Figure 3.1 111
Percentage of esterase + ye cells in the thoracic duct 
lymph of tumour bearing rats
0.23
Var B, = 0.00138
Var = 0.0169
* Tumour bearing rats
• Normal
Days
Figure 3.2
0.23
0.00138Var B.
Var B 0.015
* Tumour bearing rats 
+ C . Parvum
• Normal
Days
Percentage of esterase + ve cells in thoracic duct lymph 
of tumour bearing rats given C. Parvum 0.7 mg I.V.
Figure 3.3
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No. of esterase + ye cells in the thoracic duct lymph 
of tumour bearing rats
25 X 10 cells/hour
* Tumour bearing rats
• Normal
20.
15
-2.96
10 = -2.16
Var
1.246Var
Days
Figure 3.4
No. of esterase + ve cells in the thoracic duct lymph 
of tumour bearing rats given C. Parvum 0.7 mg I.V.
X 10 cells/hour25
20 * Tumour bearing rats 
+ C. Parvum
• Normal
15
10
-2.96
.— #.
-2.45
0.245Var B,
Var B„ = 0.256
Days
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Figure 3.5
No. of phagocytic cells on a 20 minute incubation 
in tumour bearing rats
10 cells/hour
* Tumour bearing rats
# Normal
Var = 0.0406
Var B„ = 0.0369
Days
Figure 3.6
No. of phagocytic cells on a 40 minute incubation 
in tumour bearing rats
X 10 cells/hour
* Tumour bearing rats
• Normal
P< 0.01 
B, = -0.8
Var B^  = 0.0269
Var B„ = 0.00587
Days
Figure 3.7
No. of phagocytic cells on a 20 minute incubation 
in tumour bearing rats given C. Parvum 0.7 mg I.V,
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X 10 cells/hour
* Tumour bearing rats 
+ C. Parvum
• Normal
“0.024
Var B 0.0406
0.001598Var BJ
*
1
Days
Figure 3,8
No. of phagocytic cells on a 40 minute incubation 
in tumour bearing rats given C. Parvum 0.7 mg I.V.
X 10 cells/hour
* Tumour bearing rats 
+ C . Parvum
• Normal
- 0.8
Var B, 0.0269
0.0287Var B
Days
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Chapter 4
The haematological effects of systemically administered 
C. Parvum
The effect of systemically administered C. Parvum on the 
various cell types of the blood varies widely both from 
species to species and between strains of the same 
species. Professor Halpern, commenting on this phenomenon 
at the International Conference on the effects of C. Parvum 
in experimental and clinical oncology, emphasized that the 
Merieux strain of the bacterium appears to be more toxic 
and to have greater biological effects than the Wellcome 
strain. (186) Since the alterations in the blood of virgin 
female Wistar rats after a single intravenous dose of 
0.7 mg of C. Parvum have not been reported it seemed 
important to establish these values. This was of particular 
interest when, as a result of the work described in Chapter 
2, it became apparent that this dose of C. Parvum has no 
influence on the output of lymphocytes or M.P.S. cells in 
thoracic duct lymph.
Blood was collected after cutting off the tail tip of ether 
anaesthetised female Wistar rats weighing 150-2QGG. 0.5 mis
of blood was collected .in plastic bottles containing a 
small quantity of potassium ethylenediamine-tetracetic acid 
(Brunswick) to prevent clotting. After the initial blood 
collection, 0.7 mg of C. Parvum in 0.1 ml of thiomersal was 
suspended in 0.9 mis of saline (0.9% w/v) and injected into 
the dorsal tail vein of twenty experimental rats. Serial 
blood samples were taken, one hour, one day, one week and 
two weeks after the inoculation. At the end of the series 
of blood collections the rats were killed, then their spleens 
removed and weighed. C. Parvum induced stimulation of the 
reticuloendothelial system was confirmed by the presence of 
splenomegaly. After formalin fixation, paraffin sections
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of these spleens stained with haematoxylyn and eosin were 
used in the studies described in Chapter 6 .
A series of four control rats underwent the same 
procedure for collection of bloods but instead of C.
Parvum,1 ml of 0.9% w/v saline was injected into the dorsal 
tail vein.
The blood samples were processed in an automatic analyser 
(Coulter S plus). Differential white cell counts were 
performed on Leishman stained blood smears which were 
allocated a number, but gave no indication as to the 
source of the sample. This number corresponded with the 
number on the automatic print out from the Coulter counter 
enabling subsequent interpretation of the results. The 
statistical significance of the results was carried out 
using students t test.
Results
The total white cell count was not influenced by treatment 
with C. Parvum. (Table 4.1, figure 4.1) There was a 
considerable difference between the baseline, pre treatment 
value in the two groups. As the control group comprised 
only four rats this difference can be attributed to chance. 
However, the numerical values obtained for polymorphonuclear 
leucocytes and lymphocytes in the control group are 
influenced by the low total white cell count. It is 
probably of more value to study the trends in the figures 
rather than to compare the numerical values. In the 
statistical evaluation of the results the serial values 
were compared with the baseline values in each group.
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C . Parvum treatment caused an immediate and highly 
significant increase in the count of polymorphonuclear 
leucocytes (P< 0.001) within an hour of treatment.
(Table 4.1, figure 4.2) This level had returned to 
normal within 24 hours of treatment. In the control 
group no significant alterations occurred in the polymorph 
count.
Treatment with C. Parvum caused a highly significant 
suppression of lymphocyte numbers within an hour of 
injection (P <0.001) and the following day (P<0.001)
(Table 4.1, figure 4.3) Subsequently lymphocyte numbers 
rose and by one week were just significantly higher than 
baseline values (P<0.05). In the control group lymphocyte 
numbers were suppressed within an hour of the anaesthetic 
(P <0.01) but thereafter were normal.
Both groups of rats showed similar marked falls in 
haemoglobin. (Table 4.1, figure 4.4) The C. Parvum 
treated group did not show a greater decrease than the 
control group. By the second week these levels had almost 
returned to normal.
No statistically significant alteration occurred in the 
number of monocytes in either group of rats. (Table 4.1)
Platelet counts were only performed in the treatment 
group. (Table 4.1, figure 4.5) A fall occurred within a 
day of treatment. Elevated levels were seen after one week 
followed by another fall at two weeks.
Discussion
In these studies the effects of repeated ether anaesthesia 
and loss of blood must be borne in mind. The control group 
of animals was small and was used to provide a basis for
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the comparison of trends. The normal values which were 
obtained from the pre treatment results on the 20 
treatment group rats are closely similar to published 
figures for specific pathogen free albino rats. (187)
Normal haematology values for virgin female Wistar rats 
weighing 150-2000 are not available. The pre treatment 
figures were therefore taken to be the standard values 
for these rats.
Lymphocytopaenia after C. Parvum treatment has been 
reported in animals J188) and humans (25). The control 
group of rats in this study also sustained a fall in 
lymphocyte numbers immediately after ether anaesthesia. 
However, the magnitude and the duration of the fall was much 
less than in the treatment group. C. Parvum treatment 
as given in these experiments thus causes a significant 
decrease in the numbers of circulating lymphocytes. It 
is possible that these become redistributed to tissues, 
for example lymph nodes and spleen. (Ch. 5)
As was discussed in Chapter 2 the number of lymphocytes in 
the thoracic duct is not influenced by treatment with 
C. Parvum. Since lymphocytes in the thoracic duct and the 
blood are continuously .recirculating it is difficult to 
understand why the low blood levels are not reflected in 
thoracic duct lymph. Confirmation that circulating blood 
lymphocytes are depleted by the loss of thoracic duct lymph 
was obtained by sampling venous blood after two days of 
drainage. A mean value of 1.8 x 10^ lymphocytes/litre was 
obtained from three rats confirming that loss of thoracic 
duct lymphocytes results in lymphocytopaenia.
C. Parvum injection not surprisingly results in a rapid 
immediate rise in polymorph numbers. This is the anticipated 
response to bacterial challenge. Few reports of the
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granulocyte response to C. Parvum are available. In 
human studies, Gill reported no alterations in these 
cells when studied at similar time intervals after 
intravenous C. Parvum in a dose of 5 mg/m . (96) This
observation is somewhat surprising in view of the side 
effects suffered by these patients which had all the 
features of the release of pyrogens. Milas reported 
that the granulocyte count was not influenced by 
treatment with a variety of doses of intraperitoneal 
Corynebacterium Granulosum in mice. (188) However, in 
this series of experiments the polymorph count was not 
studied until three days after treatment. The immediate 
alterations noted in the present study would not have 
been seen by these workers. It must also be remembered that 
the rats received a higher dose weight for weight.
Anaemia has been reported after C. Parvum treatment in mice 
(168). It has been speculated that C. Parvum may 
stimulate the development of anti red blood cell antibodies 
which destroy autologous red cells in conjunction with 
activated phagocytes. The anaemia found in the present 
study can be attributed to the sequential loss of blood and 
the haemodiluting effect of the 1 ml inoculum, as the fall 
in each group was the same.
Monocyte levels in peripheral blood are low and usually 
they compromise less than 2% of white cells. This makes 
it difficult to be certain about a decrease in the number 
of these cells although an increase might be apparent. 
Monocytopaenia is said to occur after C. Parvum treatment, 
(106, 25), but no statistically significant alterations 
occurred in this study. There is more universal agreement 
that C. Parvum increases bone marrow macrophage colony 
formation. (19, 188, 189)
The triphasic response of platelets to C. Parvum is in 
agreement with the findings of Castro and his co-workers. 
(190) In their experiments high doses of C. Parvum (0.46 mg)
120
were given intraperitoneally to mice. These animals were 
acutely distressed for two hours after the inoculation. 
Subsequent histological changes in the liver, lungs and 
spleens of these animals were found which had the 
appearance of disseminated intravascular coagulation.
Systemic C. Parvum in humans causes a marked fall in the 
serum level of fibrinogen with an increase in fibrin 
degradation products. (190, 191) Thrombocytopaenia is also 
sometimes found. There has been some speculation that 
the anti metastatic effect of C. Parvum noted particularly 
in the Lewis lung carcinoma model, may be due to altered 
coagulation rather than immune stimulation. (190)
Conclusions
As a result of this study it has been shown that when
0.7 mg of C. Parvum is given intravenously to virgin 
female Wistar rats the following alterations occur in the 
blood.
There is an immediate lymphocytopaenia with a slight 
rebound increase by one week.
There is an immediate increase in the polymorph count, 
probably as a response to bacterial challenge. This rise is 
not sustained and there are no long term alterations.
The anaemia which resulted could not be attributed to C.
Parvum treatment.
No firm conclusions can. be drawn about the effect of C. Parvum 
on monocytes.
The platelet response was similar to another study where 
a much higher dose of Corynebacterium Parvum was used.
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Figure 4.1
White cell count after intravenous C. Parvum 0.7 mg IV
cells
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Figure 4.2
Polymorph count after intravenous C. Parvum 0.7 mg IV
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• = Control
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Figure 4.3
Lymphocyte count after intravenous C, Parvum 0.7 mg IV
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Figure 4.4
Haemoglobin changes after I.V. C. Parvum 0.7 mg I.V.
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Figure 4,5
Platelet count after intravenous C. Parvum 0,7 mg IV
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Chapter 5
The influence, of intravenous C.. Parvum. on cells in 
peritoneal exudates and splenic macerates.________
C. Parvum treatment stimulates the anti tumour activity 
of peritoneal exudate cells (86, 192, 193, 194) and 
increases the uptake of particulate materials by the 
spleen. (2) In this section the effect of intravenously 
administered C. Parvum on M.P.S, cells in the peritoneal 
cavity has been studied. Activation of these cells 
could suppress the development of malignant cells in 
the peritoneal cavity, carrying particular implications 
for the use of I.V. C. Parvum in human gastro intestinal 
cancer.
The increased uptake of colloidal carbon after C. Parvum 
is attributed to an augmented fixed tissue macrophage 
population in the sinusoids of the liver and spleen. A 
series of experiments have been carried out to study 
whether the non fixed cell population of the spleen might 
also show increased phagocytosis after C, Parvum.
Peritoneal exudate cells (PEC) were harvested from ether 
anaesthetised female Wistar rats weighing 100-250G. 10 mis
of 0.9% w/v sodium chloride solution containing 5 
international units of heparin/ml was injected into the 
peritoneal cavity via the midline. After gently massaging 
the abdomen for five minutes the injected fluid was 
retrieved along with P.B.C. The abdomen was incised in the 
midline and the fluid aspirated with a siliconised glass 
pipette. No attempt was made to retrieve the entire 
inoculum and 5 mis was usually considered to be an adequate 
volume. Blood stained samples were discarded. After 
washing P.E.G. thrice a count was performed. Cytocentrifuge 
slides were prepared both from the washed cell sample and
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from P.E.C. which had been used as the effector cells 
in the phagocytic assay with sensitised sheep red blood 
cells. Subsequently these slides were stained for non 
specific esterase reactivity and the percentage of cells 
staining for esterase and showing phagocytosis counted.
From the original cell count the total number of esterase 
positive and phagocytic cells present per ml of the lavage 
fluid was calculated.
This study was performed in normal rats and in rats which 
had received 0.7 mg of C. Parvum I.V. one and two weeks 
previously.
In the same group of rats after peritoneal lavage had been 
performed the spleens and caecal lymph nodes were removed 
and weighed. The caecal lymph nodes lie separate from the 
rest of the mesenteric lymph chain and can easily be 
removed. 200 mg of each spleen was accurately weighed and 
subsequently macerated. This was carried out by forcing 
minced splenic tissue through a fine wire mesh into plastic 
petri dishes. A cell suspension was prepared by carrying 
this out repeatedly and rinsing the cells through the mesh 
with a fine spray of DAB/5%FCS from a plastic syringe. At 
the end of this procedure a small amount of tough tissue 
remains. It was assumed that this represents the fibrous 
stroma of the spleen. The spleen cell suspension was 
washed thrice and subsequently treated in the same way as 
the peritoneal lavage fluid.
Statistical comparisons were carried out with student's 
t test.
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Results
The weights of the spleens and lymph nodes were 
adjusted to the weight of a 100 G rat. As was 
described in Chapter 1 this eliminates the influence 
of variations in the size of the animal. Stimulation 
of the reticuloendothelial system of these rats was 
confirmed by the increase in splenic weight after 
C. Parvum treatment. This became statistically 
significant by two weeks (P< 0 .01) and showed an upward 
trend in the first week (Table 5.1, fig. 5.1) C. Parvum 
treatment did not influence the weight of the caecal 
lymph nodes.
Splenic macerates : (Table 5.1, fig. 5.2) Maceration of 
the spleen yielded a cell suspension containing low 
concentrations of both esterase positive cells and 
phagocytes. Mononuclear phagocytes showed a slight 
decrease a week after treatment but were significantly 
increased by two weeks. (P< 0.001) Esterase positive cells 
showed a similar initial downward trend followed by an 
increase after two weeks which did not attain statistical 
significance. Most of the cells, other than red corpuscles, 
seen in these preparations were large and small lymphocytes.
Peritoneal lavage : (Table 5.3, figs. 5.3 and 5.4)
A high percentage of P.E.G. had a positive staining reaction 
for non specific esterase. In untreated rats nearly 40% of 
P.E.G. were positive. Numerous large mast cells were seen in 
these samples, but not included in the cell counts. Large 
and small lymphocytes and polymorphonuclear leukocytes made 
up the remainder of cells. Phagocytic polymorphs were not 
included in the counting of phagocytes. They were clearly 
distinguished from M.P.S. cells by their segmented nuclei and 
bright pink cytoplasm. G . Parvum treatment resulted in a 
significant fall in the percentage of esterase positive cells 
within a week (P< 0.001) with a significant increase in this 
value after two weeks (P <0.01).
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Two weeks after C. Parvum treatment over 50% of P.E.G. 
were esterase positive. Phagocytic cells showed a 
similar trend of an early fall followed by a subsequent 
increase, although the figures are not statistically 
significant. Nearly a quarter of the P.E.G. obtained 
from untreated rats were phagocytic for sensitised 
sheep red blood cells confirming that this is an 
appropriate method of studying phagocytosis.
Discussion
In this series of experiments the splenic weight increase 
confirmed that reticuloendothelial stimulation had 
occurred. This dose of G . Parvum given by the intravenous 
route did not affect the weight of the caecal lymph 
nodes. Other workers have reported lymph node hypertrophy 
after systemic G . Parvum. In male GBA mice injected with 
1.4 mg of G . Parvum I.P. the mean weight of the pooled 
axillary and brachial lymph nodes was increased, 
particularly after one week. (3) G . Granulosum had a 
similar effect on the weight increase of the inguinal nodes 
in mice. (188) The dosage of C. Parvum employed by 
these workers was much greater than that used in the present 
studies. Other workers, again using mice, have found the 
response of lymph nodes to G . Parvum to be highly dependent 
on the dose employed and the route of the injection. (168)
No reference has been found on the effects of intravenous 
G. Parvum on lymph nodes draining the gut. As will be 
described in Ghapter 6, these nodes do show histological 
changes consistent with a response to G. Parvum.
I.P. G . Parvum results in a 7 to 10 fold increase in the 
cell yield after peritoneal lavage. (192) 85% of these
appear to be M.P.S. cells based on morphological criteria 
and non specific esterase staining. G. Parvum stimulated PEG 
show an enhanced tumour cytotoxicity both in vitro (192, 86 
194) and in vivo (193). The cells exerting
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this effect adhere to glass and intimate cell to 
cell contact is required. (72) Since the cytotoxicity 
is present in T cell deficient mice (54) and is impaired 
by agents selectively toxic to macrophages like silica 
(195) carrageenan (196) and gold salts, (197) it is 
probably mediated by M.P.S, cells. C. Parvum stimulated 
PEC when inoculated with methylcholanthrene induced 
fibrosarcoma cells caused significant delay in subsequent 
tumour development. (193) This action was inhibited by 
adding inert plastic microspheres to the inoculum which 
may have interfered with PEC - tumour cell contact. The 
cytotoxicity of spleen cell suspensions was not enhanced 
by C. Parvum treatment in the same group of experiments. 
These suspensions were prepared in the same manner as in 
the present study. If the tumour cytotoxic effect was 
entirely mediated by M.P.S. cells as these workers suggest 
their results would be consistent with the present 
observations. Although C. Parvum treatment does influence 
the numbers of M.P.S. cells present in spleen cell 
suspensions their actual number is small. It is probable 
that insufficient quantities would be obtained to show 
in vitro tumour cytotoxicity.
The increased phagocytosis seen after C. Parvum treatment 
has usually been measured by the rate of disappearance of 
intravenously injected substances, like colloidal carbon. 
Whole body irradiation given prior to, but not after 
C. Parvum treatment prevents this increase in phagocytosis.
(198) This has led Woodruff to conclude that the cells 
responsible for the increase in phagocytosis after C. Parvum 
treatment are mature fixed tissue macrophages. These 
mature macrophages are relatively insensitive to 
radiotherapy unlike newly formed M.P.S. cells. Provided 
the C. Parvum treatment is given four days or more prior 
to irradiation the newly formed M.P.S. cells from the bone 
marrow are radio resistant.
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The phagocytic activity of PEC is probably not measured by 
the carbon clearance test. No reference has been found on 
the direct measurement of the phagocytic capacity of these 
cells after I.V. C. Parvum.
I.V. C. Parvum causes an initial fall in the esterase 
positive and phagocytic cell populations in both peritoneal 
lavage samples and splenic macerates. Subsequently these 
cells are present in increased numbers. Although not all 
of the values achieve statistical significance it is 
noteworthy that the trend is the same in each population 
studied. The initial suppression followed by a rebound 
increase is very similar to the observations made by Gill 
on the esterase positive cell population in human peripheral 
blood after intravenous C. Parvum. (25)
Intravenous C. Parvum causes a marked increase in the 
percentage of esterase positive cells in peritoneal 
exudates. However, the value of just over 50% does not 
approach the 85% level seen after I.P. C. Parvum (193)
I.P. C. Parvum may act as a chronic inflammatory stimulus 
rather than an immune stimulant. Intrapleural C. Parvum 
has been successfully employed in the treatment of human 
malignant pleural effusions. (T.J. Priestman : personal 
communication). Used in this way the treatment is 
probably no more specific than the time honoured procedure 
of instilling talcum powder to cause an inflammatory 
reaction leading to subsequent fusion by fibrosis of the 
parietal and visceral pleura.
As a result of the observations made in this study it is 
concluded that:-
1. C. Parvum causes a significant increase in the percentage 
of esterase positive cells in peritoneal exudates after 
an initial fall.
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2. Non fixed tissue phagocytes in the spleen are 
increased as a result of C. Parvum treatment, but 
also show an initial fall. It is unlikely that these 
non fixed phagocytes are present in sufficient numbers 
to make a significant contribution to the increased 
splenic phagocytosis previously reported.
3. Gut associated lymphoid tissue does not hypertrophy 
after the dose of C. Parvum employed in this study.
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t able 5.1
The effect of C. Parvum on spleen and caecal lymph node weight
Rat weight Spleen weight Node weight
grams  x 100   x 100
Rat weight 
grams
Rat weight 
milligrams
Normal Rats 
n = 11
X  -SEM 104.8-6.5 0.22 -  0.01 1.68 - 0.74
C. Parvum 
0.7 mg IV 
X one week 
n = 12 X -SEM 213 - 66 0.3 - 0.02 1.74 - 0.9
C . Parvum 
0.7 mg IV 
X two weeks 
n = 6
X  isEM 269 - 10.7 0.42 - 0.04* 1.59 - 0.7
P < 0.01
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FXQURE 5.1
The effect of 0.7 mg C. Parvum IV on the weight of the
spleen and caecal lymph nodes
Spleen 2 ; IQO 
weight jrat weigh.t
.02
lymph, 100 
.019 node rat wt
.0180.4
.017
0.3- .016
.015
.0140.2
;013
.012
= spleen 
= node .011
;01
No C . Parvum C . Parvum C. Parvum
0.7 mg IV 
X 1 week
0.7 mg IV 
X 2 weeks
FIGURE 5.2
The effect of 0.7 mg C. Parvum on phagocytes in spleen 
cell suspensions
% phagocytë Number of 
phagocytes x 10
• = % age 
*= number
C. Parvum 
0.7 mg IV
C. Parvum 
0.7 mg IV
No treatment
X 1 week X 2 weeks
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Figure 5.3
The effect of C. Parvum 0.7 mg IV on esterase positive PEC
X 10 cells/ml
50
40
30
20
• = % esterase
phagocytic cells/ml
10
No
C . Parvum
1 2
52 52
Figure 5.4
The effect of 0. Parvum 0.7 mg IV on phagocytic PEC
T- 29.3%
Phagocytes No of phagocytes
X 10*^  cells/n24
23
22 1.7
21
20
19
18 1.3
17
o^ phagocytes* =
16 *= Number of
phagocytic cells, ml
0.9 jx 1015 '
No C , Parvum
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Chapter 6
Histological alterations after C . Parvum treatment
Tissue sections have been studied to compare the 
histological changes caused by the dose and route of 
injection of C. Parvum employed in this study with 
those noted by other workers. This has been principally 
assessed by noting structural alterations in haematoxylin 
and eosin stained sections. Acid hydrolase stains have 
also been used to see if there were any alterations in 
the numbers and the distribution of positive staining 
cells.
Treated rats either received 0.7 mg of C. Parvum in 0.1 ml 
of 0.01% thiomersal preservative made up to 1 ml with 0.9% 
w/v saline for intravenous injection, or 0.7 mg of C. Parvum 
in 0.1 ml of 0.01% thiomersal injected directly into a 
lacteal. Inoculation was performed during the two weeks 
proceeding the study. Sections were taken from the spleen, 
liver, caecal lymph node and the gut. These specimens 
were immediately flash frozen in liquid nitrogen and 
cryostat sections (Slee Medical Equipment, London) of between 
4 and 5 microns thickness cut by an experienced technician. 
The slides were stained using the following methods:
Haematoxylin and Eosin (H & E) : The slide was immersed in 
Carnoy's fixative for two minutes, rinsed in distilled 
water and placed in Bullard's haematoxylin solution for 
a further two minutes. After another wash in distilled 
water the slide was immersed in a 1% solution of acid 
alcohol for 30 seconds, then washed again until it appeared 
blue in colour. After 10 seconds in eosin solution the 
slide was dehydrated in graduated concentrations of up to 
100% alcohol prior to mounting with DPX.
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Acid Phosphatase: This was carried out by a 
simultaneous capture-coupling reaction and was done 
using a reagent pack (Sigma chemicals, Poole), designed 
for human leukocyte acid phosphatase. 2 mis of the 
substrate solution naphthol AS - BI phosphoric acid 
was added, with fast garnet crystals, to 46 mis of 
distilled water and 2 mis of acetate solution. After 
filtering the mixture the staining reaction proceeded 
in a dark oven at 37^C for twenty minutes. The section 
was counterstained with acid haematoxylin for 5 minutes 
to stain the nuclei. After washing in distilled water 
the slides were air dried. A water soluble mountant was 
used before applying a cover slip.
p Glucuronidase: A stock substrate solution was made 
up by dissolving 28 mg of naphthol - AS - BI Glucuronic 
acid in 1.2 ml of 0.05 M Sodium hydrogen carbonate.
The volume was adjusted to 100 ml with 0.2 M acetate buffer. 
10 mis of the substrate solution were added to 0,6 ml of 
hexazotised pararosaniline prepared as for the non 
specific esterase stain. The pH of the resulting 
staining solution was adjusted to 5.2 with 0.1 M NaOH and 
the final volume was made up to 20 mis with distilled water. 
The staining solution was filtered and applied to the 
slides which were fixed in formalin vapour for 30 seconds. 
Staining took about 30 minutes and was carried out at 37^C 
in a dark oven. Finally the sections were washed, 
counterstained with Giemsa and then mounted with DPX.
Non specific esterase: The method used was the same as has 
been described for the staining of cytocentrifuge 
preparations (Chapter 2). Before staining, the tissue 
sections were fixed in formalin vapour for 1 minute.
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The area measurements of the splenic white pulp were 
calculated with the aid of a computer linked microscope 
(MOP AMO3). After placing the slide under the 
microscope the image was projected onto a metal grid 
surface. Using an electronic pen, linked to the 
computer, a line was drawn round the perimeter of the 
area to be measured. A value for this area was then 
computed and a typed print out obtained. The statistical 
significance of the observations was calculated from the 
standard error of the difference of their respective 
means.
Results
Splenomegaly was present in all rats which had received 
C. Parvum, whether by the I.V. or the lacteal route. This 
was taken to confirm that reticuloendothelial stimulation 
had taken place.
As the lacteal inoculum of C . Parvum reached the caecal 
lymph node it immediately distended and blanched. When 
the node was removed between 7 and 14 days later it was 
found to be considerably enlarged and surrounded by 
inflammatory adhesions. C. Parvum is provided as a 
suspension of the killed organism in thiomersal 0 .01% as 
a preservative. As a control experiment, 0.1 ml of 0.01% 
thiomersal was injected into the lacteal. No acute 
alterations occurred in the node, which appeared 
macroscopically normal when removed between 7 and 14 days 
later. Splenomegaly did not occur in the control rats. 
Direct injection of C . Parvum into the caecal lymph node 
caused a considerable increase in the weight of the node. 
(Table 5.1) Intravenous C. Parvum caused no alterations 
in the node weight but histological changes were seen. 
Marked expansion of the sinus was noted both one and two
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weeks after treatment. (Plates 6.1) There were also 
increased numbers of developing follicle centres in the 
cortex. (Plate 6.2)
After direct intralacteal C. Parvum the node suffered 
considerable disruption. Large areas showed complete 
architectural destruction with necrosis. (Plate 6.3)
The residual lymphoid tissue around the central zone of 
necrosis contained granulomas and giant cells. None of 
these features were present in the control group of rats.
The spleen showed considerable expansion of both the red 
and white pulps, (Plates 6.4 and 6.5) A comparison of 
the mean areas of the white pulp in normal and treated 
rats has permitted a statistical comparison to be made. 
(Table 6.2) Both I.V. and I.P. C. Parvum caused a highly 
significant increase (P < 0.001) in the area of the white 
pulp compared to normal. In addition the I.V. C. Parvum 
induced increase was statistically greater than the I.P. 
increase. (P< 0.025)
These measurements were only made on the white pulp but 
the red pulp appeared to show a similar size increase,
C. Parvum treatment resulted in considerable expansion of 
the lymphoid follicles. Large perivascular cuffs of pale 
staining macrophages were seen. Numerous developing 
granulomata were present. (Plate 6.6) By three weeks after 
the injection there were numerous vacuolated cells 
throughout the red pulp having the appearance of macrophages 
and the overall picture was that of a brisk reactive process
Cells showing a positive reaction for acid hydrolase 
stains were virtually restricted to the splenic red pulp,
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(Plates 6.7, 5.8 and 6.9), Acid phosphatase stains 
showed some activity in the mantle zone of the white 
pulp. The density of staining and the number of 
positive staining cells did appear to be increased by 
C. Parvum treatment, but no quantitation of this 
response has been attempted. The increase appeared 
to be in proportion to the increased size of the red 
pulp.
When these staining methods were used on cryostat sections 
of the liver extensive positive staining was obtained.
In the gut a few positive cells were found at the bases 
of the crypts of Lieberkuhn. Scattered positive 
staining was found in the lymph nodes. In none of these 
tissues was it apparent that C. Parvum treatment had 
influenced the extent of the staining reaction.
Discussion
In Professor Halpern’s original report of the increased 
phagocytosis resulting from C. Parvum treatment the 
changes in histology were also described. (2) This and 
subsequent studies describing histological alterations 
were performed in mice. (3, 168, 188) In Halpern's 
study the mice were injected repeatedly with C. Parvum 
at a dose of 255 ;j.g. An increase was reported in cells 
which ingested carbon in both the liver and the spleen. 
Numerous granulomata were found in both of these organs. 
Although the liver and spleens continued to increase in 
weight throughout the eight injections the increased 
phagocytic capacity began to fall after the fourth 
injection.
The increased weight of the caecal nodes noted after 
intralacteal C. Parvum may have been largely due to
142
surrounding inflammatory tissue. When these nodes 
were excised they were densely adherent to surrounding 
structures making accurate dissection difficult. As 
can be seen from Plate 6.^ there was no evidence that 
this form of treatment had any stimulatory effect on 
the draining node. In fact after treatment it was 
difficult to identify normal functioning lymphoid 
tissue.
Increased activity in the germinal centres of the lymph 
nodes has also been reported by Milas. (188) In his 
study Corynebacterium Granulosum was given in high doses. 
This bacterium is closely related to C. Parvum and its 
systemic use results in similar stimulation of the 
reticuloendothelial system. Marked depletion of 
the cell content in the splenic white pulp resulted from 
this treatment which became most marked after two weeks. 
However, the dose employed was as high as 0.5 mg and the 
most extreme depletion resulted from repeated injections.
The lower doses of C. Parvum employed by McBride and his 
co-workers resulted in histological changes in the spleen 
which were very similar to the present study. (168) Using 
70 yig - 240 p.q I.P. in mice they found expansion of both 
the red and white pulps of the spleen. The acid phosphatase 
activity of glass adherent spleen cells showed a threefold 
increase over that of controls.
It seems probable that low doses of C. Parvum stimulate 
lymphocytes while higher doses are toxic.
The dose of C. Parvum employed in this study does appear 
to have caused major alterations in not only the size but 
the cell population of lymphoid organs. No alterations 
were seen in the sections taken from the large bowel 
and liver. No granulomata were found in the liver
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but the dose used in this study was considerably lower 
than Halpern's. Direct inoculation of C. Parvum into 
a lymph node has not been previously reported. The 
dramatic destruction of the lymph node which results 
may indicate that some acute hypersensitivity reaction 
occurs. Animals and humans (87) show background anti 
C. Parvum antibody titres which suggests that prior 
exposure to the organism is common. It seems probable 
that the splenomegaly which resulted from this treatment 
was the result of the injected C. Parvum gaining access 
to the general circulation rather than local processing 
in the lymph node.
It had been proposed to examine the dimethyIhydrazine 
induced colonic cancers using these staining techniques. 
However, some tumour cells take up non specific esterase 
stains and the assessment of tumour macrophage populations 
on the basis of this stain reaction could be misleading.
(199)
Whether acid hydrolase and non specific esterase stains 
can act as markers for M.P.S. cells is open to question. 
Other cells, for example polymorphonuclear leukocytes can 
show positive staining reactions. Although these can be 
distinguished on morphological grounds it is likely that 
much improved specificity of staining will result from the 
use of monoclonal antibodies.
Conclusions
1. Systemic C. Parvum results in considerable expansion 
of both the red and white pulps of the spleen. There is 
evidence to suggest that M.P.S. cells are increased in 
number.
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2. Systemic C. Parvum causes sinus hyperplasia and 
increased activity in the germinal centres of lymph 
nodes.
3. Intralacteal C. Parvum is directly toxic to the 
draining lymph node and subsequently exerts a systemic 
action.
4. It was not possible to quantitate C, Parvum induced 
alterations in tissue sections using acid hydrolase 
stains.
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Plate 1 : Cytocentrifuge preparation 
of thoracic duct lymph x 4Q Giemsa. 
Large and small lymphocytes, MPS cells 
showing processes and cytoplasmic 
staining for N.S.E..
Plate 2 ; Cytocentrifuge preparation 
of thoracic duct lymph after 
phagocytosis of sheep red blood cells 
Note; one phagocytic cell shows 
cytoplasmic staining for N.S.E. x 40 
Giemsa.
Plate 3 ; Carcinoma of rat colon x 10 
H & E. The typical appearance of a DMH 
Induced colonic cancer.
Plate 4 : Carcinoma of rat colon x 40 
H & E . Pleomorphic cells hyper- 
chromatlc nuclei, signet ring cells 
and abnormal mucin deposition.
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Plate 6.1 ; Caecal lymph, node x 12 
H & E. Sinus hyperplasia after I.V. 
C. Parvum.
Plate 6.2 ; Caecal lymph node x 40 
H & E. Developing follicle centre 
after I.V. C . Parvum.
Plate 6.3 ; Caecal lymph node x 15 
H. & E .. Extensive necrosis after 
Intralacteal C. Parvum.
Plate 6.4 Normal spleen x 10 H. & E. Plate 6.5 ; Spleen two weeks after 
I.V. C. Parvum x 10 ff. & E..
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Plate 6.6 : Spleen H & E x 40. 
Granulomata developing In white pulp 
of spleen after I.V. C. Parvum.
Plate 6.7 ; Spleen x 40 
B glucuronidase. Positive 
staining In red pulp.
%  “
*
Plate 6.8 ; Spleen x 40 non specific 
esterase. Positive staining In red 
pulp.
Plate 6.9 ; Spleen x 40 acid 
phosphatase. Positive staining 
in red pulp and mantle zone of 
white pulp.
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TABLE 6.1
The effect of C. Parvum on the mean weight of the caecal 
lymph nodes.
Number of 
nodes 
weighed
Mean weight 
in mg
_SEM
mg
Normal 1.68 0.74
C. Parvum 0.7 mg 
IV X one week 1.74 0.9
C. Parvum 0.7 mg 
IV two weeks before 1.59 0.7
Intralacteal 
Thiomersal 0.01% 
0.1 ml 1-2 weeks 
before 1.97 0.55
Intralacteal 
C. Parvum 0.7 mg 
in 0.1 ml of 0.01% 
Thiomersal 1-2 
weeks before 8.7 2.3
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Table 6.2
The effect of C, Parvum on the mean area of eplenfc white pulp
Number of areas 
of white pulp 
counted
Mean area Standard
deviation
1.
2.
3.
4.
Normal
Normal
57
31
C. Parvum 0.35 mg
ly two weeks previously 33
C. Paryum 0.7 mg
ly two weeks previously 26
5. C. Parvum 0.7 mg IV 
two weeks previously 63
6 . C . Paryum 0.7 mg IP
two weeks previously 59
860
763
1585
2872
2399
1915
542
521
764
1325
1468
1237
4.
4.
5. 
5.
3.
3.
1 .
2 .
1 .
2 .
1 .
2 .
P < 0.001
4,
5.
V 6.
V 6.
P < 0.0027
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Chapter 7
A clinical trial of specific active immunotherapy using 
C . Parvum with autologous irradiated tumour cells in 
surgically treated Stage I and 2 lung cancer
While surgical excision remains the cornerstone in the 
management of potentially curable cases of lung cancer, 
it is depressing to note that this most favourable group 
of patients has a five year survival rate of only 25-30%.
(200) These patients, suffering from what is considered 
to be 'early cancer', i.e. localised to the lung or, at 
most involving the draining lymph nodes, commonly harbour 
more extensive disease than is revealed by surgery. Indeed 
a survey of post morterns on these patients dying of post 
operative complications within a month of operation revealed 
that 35% harboured residual disease (local plus metastatic
(201)). Some form of additional treatment therefore seems 
justified. Chemotherapeutic agents which appear to possess 
activity against advanced lung cancer can cause considerable 
long and short term toxicity. In addition these drugs are 
of low patient acceptability when used in this post surgical 
adjuvant role. They may also be responsible for increased 
morbidity, especially as many of these patients are in poor 
general health. Nor is there any clear evidence to suggest 
that this approach improves survival. (202)
Immunother apy
The occurence of post operative empyema may improve the 
prognosis after surgery in lung cancer. (203) When this 
action was mimicked using post operative intrapleural 
B.C.G. a similar improvement in prognosis was observed, 
though only in patients with Stage 1 disease. (204) The
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appearance of sinus hyperplasia in the draining lymph 
nodes (29) and active macrophages around the primary 
tumour (28) apparently indicate a favourable prognosis, 
and suggests that the patients immune system has 
recognised a tumour specific antigen and is capable of 
reacting against it. On the other hand depression of 
cell mediated immunity in advanced malignant disease is 
both common and of poor prognostic significance. (30,
205)
A clinical trial was planned using autologous irradiated 
lung cancer cells which were re-injected into the dermis 
of the thigh, along with a very small dose of C. Parvum 
during convalescence. This route has been shown to induce 
strong specific anti tumour immunity in experimental 
animals resulting in prolonged survival and immunity to 
rechallenge by the same tumour. (206)
Patients
95 patients with histologically confirmed cancer of the 
lung were included in the study. Randomisation was carried 
out per-operatively by the surgeon responsible for the 
procedure, when he was of the opinion that all macroscopic 
tumour had been resected and anticipated a relatively 
smooth post operative course. Randomisation tables were 
used and slips placed in sealed envelopes which were opened 
in sequence. Allocation was to a no treatment arm when 
routine follow up alone was carried out, or to treatment 
with autologous tumour cells. Patients were staged 
subsequently, after pathological analysis of the resected 
specimens. Stage 1 patients were those who had tumour 
localised within the lung and Stage 2 had involvement of 
the draining nodes but no distant dissemination.
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If a patient was randomised to treatment then a sample
of fresh tumour was taken immediately from theatre and
a cellular suspension prepared under sterile conditions.
No enzymes such as collagenase were used, and the
procedure consisted of fine maceration followed by
several washes in Eagles Medium. The final suspension
was tested for cell viability by exclusion of trypan
blue, a count performed and then stored, after controlled
rate freezing, at -140 degrees centigrade. Treatment
was given during convalescence, between 14 and 28 days
after surgery. On the day of treatment a sample
6containing 20 x 10 tumour cells was irradiated with 
10,000 rads and 30 fig C. Parvum added with medium to a 
final volume of 1.5 ml. The rationale for combining these 
tumour cell numbers with a small dose of C. Parvum is based 
on animal studies showing that this relationship is 
critical and that higher doses of C. Parvum can enhance 
tumour development. (84, 207)
The trial was approved by the ethics committee of the 
Oxford Area Health Authority and informed consent was 
obtained from all patients randomised to immunotherapy.
The statistical significance of the results has been 
analysed by the log rank test. Life tables have been 
prepared as described by Peto and Pike and by using a 
computer programme designed by these authors. (208)
Results
A total of 95 patients have been included in the trial,
49 in the control group and 46 in the treatment group.
In each group the average age of the patients was similar 
and patients were predominantly male. 9 out of a total of 
14 female patients are in the control group. If all the 
patients randomised to therapy are considered then the
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treatment group has shown an apparently poorer survival 
but this is not significant (Table 7.1, figure 7.1).
However, in this group, 12 patients did not receive 
treatment. 6 patients were either too unwell or died post 
operatively, 2 did not attend the follow up clinic 
on the day of treatment, 2 were suspected of harbouring 
residual disease on review and in 2 a satisfactory cell 
suspension could not be prepared. In the control group 
3 patients died within 3 months of operation and the 
remainder were well at the first review. If patients 
not surviving 3 months after operation are excluded 
from the analysis then the groups are even rt^ ore similar. 
(Table 7.2)
When the outcome is assessed according to the stage of 
spread of the tumour at operation, the anticipated poor 
results are seen after surgery in patients with involvement 
of the regional lymph nodes (Table 7.3, figure 7.2),
Treatment does not appear to have affected the outcome in 
either Stage 1 or Stage 2 disease. It can be seen that 13/45 
of patients in the treatment group had Stage 2 disease 
compared with 11/49 in the control group.
8 of the 13 treatment patients with Stage 2 tumours are 
dead at a median time-interval of 9.1 months after 
operation. This compares with 6 of the 11 control patients 
with this stage of disease who had a median survival of 
only 6.2 months.
Table 7.4 shows that there was an equal distribution of 
histological types in the two groups. Although it had been 
intended to exclude patients with small cell tumours from 
this trial, 3 such tumours were diagnosed on the histology 
of the resected specimens after randomisation. These have
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been retained and the two patients with this histology 
in the treatment group were given immunotherapy. The 
table shows that treatment has not improved survival 
in any histological type. It is of interest to note 
that all 7 patients with a diagnosis of adenocarcinoma 
who survived by 3 months are still alive at median time 
intervals from surgery of 23 months in the treatment 
group and 15.5 months in the control group.
Four out of five patients with anaplastic cancer in 
the treatment group survived longer than 3 months from 
surgery. All of these patients are still alive at a median 
time of 10 months. The small numbers involved in this 
group make conclusions difficult.
When survival is assessed according to the nature of 
the operation (Table 7.5) performed there is no significant 
difference in the results. This analysis has been made on 
patients surviving more than 3 months after the operation 
and 17/40 (42.5%) treatment patients had a pneumonectomy 
.compared with only 10/46 (22%) controls. It is apparent 
that the patients randomised to immunotherapy were 
suffering from rather more extensive disease. This may 
explain the greater number of post operative deaths in the 
treatment group of patients.
Discussion
Attempts to increase anti tumour immunity in human 
malignancies must be at least partly based on empiricism.
The results of laboratory experiments may be helpful but 
are not necessarily of direct clinical relevance. While 
tumour specific antigens can be identified in artificially 
induced malignancies in experimental animals (40) this 
is not yet true in human cancer. Although there is indirect
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evidence both for the presence of tumour specific antigens 
and host immune reactivity against these putative 
antigens, the mechanism of the host response to cancer 
remains unclear.
It has been claimed that immunotherapy with allogeneic 
tumour cells and B.C.G. given intradermally after surgery 
for Stage 2 malignant melanoma resulted in a 50% reduction 
in métastasés as compared with an histological control 
group (56). However, a very similar trial in this country 
using concurrent control patients showed an alarming 
trend towards early recurrence in the treatment group and 
the trial was brought to an early halt (58).
Numerous trials of immunotherapy have been reported in 
both early and late cases of lung cancer. In many of these 
trials immune stimulation was combined with either chemo or 
radiotherapy, thus making the result somewhat difficult to 
interpret (209).
B.C.G. along with irradiated allogeneic tumour cells has 
been given intradermally to patients suffering from all 
stages of lung cancer. The results have been compared with 
groups who received B.C.G. alone or no additional treatment 
There was no benefit from treatment in advanced disease, 
but patients with Stage 1 and 2 disease have not yet been 
evaluated (210). The interpretation of the results of 
this treatment was complicated in Stage 3 patients as 
radiotherapy or chemotherapy were added as considered 
clinically indicated.
Claims of benefit after surgery for Stage 3 tumours have 
been made after using autologous tumour cell vaccine 
treated with vibrio cholera neuramidase and concanavalin 
A then injected intradermally with Freunds complete 
adjuvant. However, as the treatment group of patients
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required less extensive surgery and had a higher 
proportion of patients with adenocarcinoma the 
interpretation of the claim of benefit is open to 
doubt (211).
A controlled randomised trial of intrapleural B.C.G. in 
surgically resected lung cancer carried out in this 
country failed to confirm the experience of McKneally 
(212). The authors point out various minor differences 
in the treatment given but it seems unlikely that these 
were sufficient to explain the differences in results 
between the two trials.
By administering a cellular suspension of autologous 
tumour cells which were irradiated to prevent local 
implantation or dissemination, and combined with a small 
dose of C. Parvum, it was hoped to augment host resistance 
to any residual lung tumour. By injecting this vaccine 
in the thigh where it would drain to lymph nodes unlikely 
to have had previous exposure to the tumour antigen, 
and by using C. Parvum for its adjuvant effect (105) it 
was hoped that these immunocompetent nodes might produce 
specific anti tumour antibodies. Careful analysis of the 
results fails to show that any such beneficial effect has 
occurred. However, it,does not appear that there have 
been any adverse effects from this type of therapy and 
side effects were minimal.
In reviewing the results of this trial it was clear that 
the interpretation was made more difficult because of the 
large number of patients (almost 25%) who although 
randomised to treatment did not receive it. This could 
probably have been avoided if tumour samples had been 
prepared from all patients considered by the surgeon to 
be suitable for inclusion in the trial. Randomisation could
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then have been deferred until the patient had made a 
satisfactory recovery from the operation. Prior to 
discharge those patients who had drawn treatment could 
be given a full explanation of the proposed immunotherapy 
with the option of declining at this stage. It is likely 
that more treatment patients would actually have 
received the vaccine had this approach been adopted.
The overall results of immunotherapy in lung cancer are 
not encouraging. We do not feel that any long term 
benefit is likely to result from the approach we have 
adopted in this trial. It seems unlikely that this form 
of treatment will become relevant until lung tumour 
specific antigens can be identified, assuming they exist. 
The recent advances using hybridoma derived monoclonal 
antibodies suggest that this may not be such a remote 
long term aim (213).
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Table 7,1
Overall Death Rate
Treatment Control
Number 46 49
Deathe
Mean time to death.
Figureg in parenthesis indicate percentage of total in the group
20 (43.5%) 17 (35%)
1.25 mths 13.1 mths
Table 7.2
Death rate excluding patients dying within 3 months of surgery
Treatment Control
Number
Deaths
Mean time to death
40
14 (35%) 
17.3 mths
46
14 (30%) 
15.6 mths
Figures in parenthesis indicate percentage of total in the group
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Table 7.3
Overall survival according to tumour stage at operation
Treatment Control
alive 21 27
Stage 1
dead 12 (14.8) 11 (16.8)
alive 5 5
Stage 2
dead 8 (9.1) 6 (6.2)
Mean time interval in months in parenthesis
Table 7.4
Histological type and death rate of patients surviving 
3 months
Treatment Control
Squamous 33 (14) 34 (9)
Adenocarcinoma 3 ( 0) 4 (0)
Anaplastic 4 C 01 8 (5)
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Table 7.5
Survival according to operation of patients living 
3 months post-op
lobectomy pneumonectomy
No Time in No Time in
months months
alive 17 9
Treatment
dead 6 20.3 8 13.5
alive 27 5
Control
dead 9 11.4 5 12.2
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Chapter 8
A trial of non specific immunotherapy using systemic 
C . Parvum in treated patients with Dukes B and C 
colorectal cancer
In 1977 cancer of the colon and rectum caused 16,462 
deaths in England and Wales (214), Advances in surgical 
technique have made no significant difference to the 
prognosis of the patient presenting with this disease.
■ An analysis of the results of surgery in the Oxford 
region (215) gave figures similar to those from Birmingham 
(216) and Bristol (217). After excision of Dukes B 
cancers patients had an age adjusted 5 year survival rate 
of 58%. In Dukes stage C this dropped to 27.1%. While 
specialised centres of referral can report figures 
considerably better than these (218) it seems likely that 
our own results are more representative of those of the 
country as a whole. These results are particularly 
depressing when it is considered how often the surgeon 
is confident that he has removed all traces of malignant 
tissue.
It is against this background of disappointment that 
consideration has been given to additional treatment 
after surgical excision of these cancers. (Ill, 112)
Colorectal Cancer and the Immune System
The recognition of a circulating antigen in the serum of 
patients suffering from colorectal cancer suggested that 
a genuinely tumour specific antigen had been found in a 
human malignant disease (41). Although this specificity 
has now been disproven, the association is nevertheless 
of importance. Elevated serum levels of "carcinoembryonic 
antigen" are found in most cases of colorectal cancer and.
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perhaps of more practical importance, revert to normal 
after tumour excisionjbecoming elevated again when 
secondary cancer develops.
Although tumour specific antigens have not yet been 
demonstrated in human cancer, considerable supportive 
evidence suggests that they are present.
Patients lymphocytes are cytotoxic for cultured tumour 
cells. (219, 220) This is true when the tumour cells 
were autochthonous (the patients own tumour), or 
allogeneic (tumour from another human). These lymphocytes 
are not cytotoxic when cultured with normal cells or 
tumours from organs other than large bowel and pancreas.
The presence of a strong capacity for lymphocyte mediated 
tumour cell destruction might be expected to confer an 
improved prognosis. That this is not the case may be 
explained by further m  vitro experiments. Autologous 
serum admixed to the lymphocyte/tumour cell culture 
prevents the lymphocyte mediated tumour cell destruction. 
(221) The serum components responsible are termed 
"blocking factors". Circulating tumour antigens and 
antigen - antibody complexes have been implicated.
Soluble extracts of tumour cell membranes have been 
prepared from human colorectal tumours. These preparations 
have been used as skin test antigens. A delayed type of 
hypersensitivity response results when these extracts are 
used on patients suffering from colorectal cancer, with no 
response in normal patients. No such response occurs when 
similar preparations are made with normal colons. (222) 
This again suggests that recognition and response to 
tumour antigens has occurred.
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Colon cancer cell preparations suppress the migratory 
capacity of mononuclear cells from tumour bearing 
patients. (223) Monocytes from normal patients are 
not affected. Preventing the influx of mononuclear 
cells might further depress cell mediated immunity.
Immune reactivity, as measured by skin testing of 
patients, lymphocyte numbers and the response of 
lymphocytes to mitogen stimulation, is suppressed even 
in early colorectal cancer. (224)
These vitro studies support the viewpoint that tumour 
specific antigens are present in colorectal cancer and 
that they evoke a cell mediated immune response which can 
be blocked. Although the clinical importance of these 
observations is unclear, it seems reasonable to assume 
that the restoration of immune responsiveness should be 
beneficial.
The effect of C. Parvum in animal and human tumours has 
been fully discussed. (Introduction) In view of the poor 
prognosis for patients who present with Dukes B and C 
colorectal cancers this group was selected for a trial 
of regular systemic infusions of C. Parvum in the two 
years after surgery. ,ln this time period many relapses 
occur and immune stimulation should be of maximal benefit 
when used in the patient bearing minimal residual disease. 
(Ill) It was also of interest to see if C. Parvum treatment 
would influence the development of distant métastasés.
Animal experiments suggested that systemic use of C . Parvum 
would have a greater effect in suppressing métastasés than 
local recurrence of tumour. (63)
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Patients
Patients were considered for inclusion in the trial 
during convalescence after surgery for pathologically 
confirmed Dukes B and C carcinoma of the colon or 
rectum. Dukes stage A patients were excluded in view 
of their excellent prognosis and Dukes stage D patients 
because of the improbability of immune stimulation being 
effective against an extensive bulk of tumour tissue. 
Treatment was with a series of intravenous infusions 
of C. Parvum in a dose of 5 mg/m given in a diluting 
volume of 100 mis of normal saline over a period of 
30 minutes. The first treatment was within a month of 
operation and in each patient it was planned to give 
ten infusions in the two years after surgery. Treatment 
usually involved an overnight stay in hospital, but some 
patients were able to be allowed home within 8 hours of 
beginning the infusion. At the beginning of the trial 
the reported side effects of intravenous C. Parvum 
included hypertension and hypotension and in view of this, 
patients who were known to suffer from cardiovascular 
disease, hypertension or pulmonary disease were not 
considered for treatment. Patients with a history of 
allergy and those over the age of 75 years were also 
excluded. The side effects of this treatment were similar 
to those previously reported (93, 94, 95) and have already 
been discussed in the introduction. The statistical 
analysis of the survival curves has been carried out by 
drawing life tables and applying the log rank test. (208)
Results
A total of 44 patients were randomised into the treatment 
group and 48 into the control group. (Table 8.1) The 
average age of the control patients was rather less than
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that of the treatment group, being 58.9 years and 
63.4 years respectively. The sex distribution between 
the groups was unequal. 38.6% (17/44) of the treatment 
group were males compared with 66.6% (32/48) in the 
control group.
When the Dukes stage of the tumour is considered there 
have been almost the same number of Dukes stage B tumours, 
but more Dukes C lesions in the control group of patients. 
(Table 8.2)
Recurrence of cancer has occurred to date in 25% of the 
treatment patients (11/44), but nearly 30% (13/44) of 
this group are dead. (Table 8,3, figure 8.1) Three of 
these have been from causes other than colorectal cancer. 
One patient suffered from a myocardial infarction after 
a period of C. Parvum induced hypotension early in the 
study. (96) One other patient died from an unexpected 
myocardial infarction during an apparently uneventful 
convalescence and before receiving C. Parvum treatment.
The third patient died from the effects of a second 
malignancy in the uterus, histologically confirmed as 
unrelated to her colonic cancer. .An almost identical 
percentage of the control group of patients have developed 
signs of recurrent cancer. Although the recurrence rate 
is 27% (13/48) the percentage who are dead is rather lower 
than in the treatment group, being 25% (12/48). Only 
one death in the control group was not due to recurrent 
cancer. This was in a patient who died from acromegalic 
cardiomyopathy. The mean time interval till recurrence 
is virtually identical, being 17.3 months in the treatment 
group compared with 17 months in the controls. Nine 
patients developed recurrent cancer during the course of 
C. Parvum infusions. When the life table analysis method 
was applied to the survival figures according to the Dukes
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stage there was no difference between the two groups 
(Figure 8.2).
Table 8.4 shows the principal sites where tumour recurrence 
first became evident. It does not appear that treatment 
has had any influence on the pattern of recurrence.
Although it was planned to give ten infusions of 
C. Parvum, it became apparent that in many patients it 
would not be reasonable to pursue this. Tolerance to the 
side effects of C. Parvum was anticipated to increase 
after the first few infusions. However, this only 
occurred in the minority of patients and in only 7 out of 
the 44 patients has the full course been given. However, 
over half of the group have received five or more infusions. 
Eight patients randomised to treatment did not receive 
any. These have been included in the analysis of the 
figures as treatment patients. One of these was the lady 
who died of a myocardial infarction during convalescence. 
The other seven patients declined treatment having 
previously given informed consent prior to randomisation.
As a full discussion of the side effects and nature of 
the proposed treatment took place prior to randomisation 
it is understandable why these seven patients had second 
thoughts about undergoing the infusions once they were 
discharged from hospital. No subsequent attempt was made 
to persuade these patients that they should have treatment.
Discussion
The poor outlook for Dukes stage B and C colorectal 
cancer has prompted many other clinical trials of adjuvant 
treatment after surgery. (93, 94) In several of these, 
chemotherapeutic drugs, commonly 5- fluorouracil, (5-FU) 
have been used.
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A significant improvement in the 5 year disease free 
survival has been reported in both Dukes B and C cancers 
by using 5-FU in two intensive five day courses. (225)
In this report, 81.6% of Dukes B and 57.5% of Dukes C 
patients were alive with no evidence of disease five 
years after surgery. These results appear to have been 
confirmed by two randomised controlled trials of post 
operative 5-FU treatment. (226)
In many trials chemotherapy, usually with 5-FU, was
combined with attempted stimulation of the immune system.
The most commonly adopted means of immune stimulation
has been repeated doses of B.C.G. usually administered
by scarification. As this treatment was often very
unpleasant, painful and sometimes caused local
ulceration, fractions of the B.C.G. cell wall have also
been used since these were thought to be less likely to
cause side effects. The results from most of these trials
are inconclusive or not yet published. Where claims of
benefit have been made, for example by the M.D. Anderson
group, the randomisation procedure has been open to
question. (226) This group of workers have treated
patients after surgery for Dukes C cancers in two ways.
Some patients received repeated scarification with B.C.G.
alone while others had the same treatment combined with
oral 5-FU. B.C.G. treatment involved scarification weekly
for three months then on alternate weeks. 5-FU treatment
2involved 150 mg/m of the drug taken orally four times a 
day for five days, once every four weeks for two years. 
Each group had a prolonged disease free interval and a 
survival curve that matched that of an historical control 
group of patients who suffered from Dukes stage B cancer. 
Since both treatment groups had similar disease free 
intervals and survival times it seemed reasonable to 
attribute this to the B.C.G. scarification rather than the
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5-FU. However, these figures have been criticised 
mainly because of the use of historical control groups.
The apparent improvement in the treated Dukes C 
patients could well have been due to some other 
alteration, for example a change in the type of patient 
presenting for surgery. This seems particularly 
relevant when the survival curves of the control group 
are carefully considered. The control group of Dukes C 
patients appears to have fared particularly badly hence 
the improvement in prognosis for both treatment groups 
may be more apparent than real.
Israel's report of the beneficial effect of systemic 
C. Parvum in advanced human malignancy engendered 
considerable enthusiasm for this approach. (95) However, 
proof of clinical benefit is now difficult to find. The 
ability of a treatment to influence the growth and spread 
of tumours in laboratory animals may support the 
investigation of its use against human malignancy. But 
laboratory results are not necessarily of clinical 
relevance. Even in laboratory animals systemic C. Parvum 
has a relatively weak action against large tumour masses 
and is more effective in suppressing the development of 
métastasés. C. Parvum as used in our trial has not 
influenced the pattern of recurrence of disease. In 
clinical practice it is often impossible to be sure of the 
extent of recurrence of cancer and for the purpose of this 
trial the most obvious sites of recurrence have been 
assumed also to be the main sites. The majority of recurrences 
in both groups have been within the abdominal cavity. In 
a few cases recurrence appeared to be genuinely localised, 
for example at the site of the anastomosis or involving 
structures near the site of the original tumour excision.
Two patients in the control group had second resections 
for locally recurrent cancer and both are still alive at
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time intervals of 30 and 23 months from their second 
operations. This supports the view that "second 
look" surgery in colorectal cancer is justified.
This trial was carried out over a time course of 54 
months. All patients randomised into the trial have 
been followed up until the closing date. Both the 
treatment and the control groups of patients show 
improved survival figures when compared with the 
retrospective study on patients presenting with 
colorectal cancer in Oxford reported by Gill et al (215). 
This is probably explained by considering the highly 
selected nature of the relatively fit patients who were 
included in the trial. The observation also serves to 
emphasise the dangers in the use of historical control 
groups.
In the early part of the trial one patient suffered a 
myocardial infarction 24 hours after his second pulse of 
C. Parvum treatment. The first infusion had been 
tolerated well. During the second infusion the patient 
became hypotensive but appeared to recover from this 
uneventfully. Some 12 hours after the infusion the 
patient developed crushing chest pain and subsequently 
died with irrefutable -electrocardiographic evidence of 
acute myocardial infarction. Rather than bring the 
trial to a halt, a more rigid exclusion policy was 
adopted. Any patient with the least suspicion of cardio 
pulmonary disease was thereafter not considered for 
randomisation. With this policy no further tragedies 
have occurred. However, this has resulted in very low 
input into the trial. A high percentage of otherwise 
suitable patients have been excluded because of concern 
about the side effects of therapy. Another effect of this 
policy has been to result in a very highly selected group
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of patients being studied. The recently reported side 
effects of human lymphoblastoid interferon (227) seem 
very similar to those of C. Parvum. This may seriously 
limit the number of patients in whom this interesting 
form of treatment can be evaluated.
At the beginning of this trial it seemed reasonable to 
aim for a course of infusions. Unfortunately the 
tolerance which was reported to build up after the first 
few infusions only developed in the minority of our 
patients. Indeed some patients suffered from increasingly 
severe side effects. Seven patients had the full course 
of ten infusions and only one of these has developed 
recurrent cancer. Nine patients developed signs of 
recurrence during the two years of treatment. Most of 
the other patients who did not complete the course of 
treatment were withdrawn by the investigating team, but 
two found the side effects intolerable and requested that 
treatment be stopped.
One objection to the use of immunostimulants is that of 
lack of specificity for target cells. If the proposed 
anti-cancer drug were to increase a population capable 
of blocking naturally occurring tumour defences, for 
example suppressor T cells, then enhanced tumour growth 
might result. None of the early human studies on advanced 
human cancers supported this viewpoint, but there was a 
clear need for caution in monitoring the progress of the 
patients in our trial. Some patients in both groups 
developed recurrent tumours within 12 months of surgery, 
but there was no difference in the mean time taken to 
tumour recurrence in either group.
Input to this trial has now ceased. There has been no 
evidence that C . Parvum has influenced the development
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of tumours used in this way in this group of patients. 
It is still premature to say what the long term effects 
will be and the results should be reassessed in the 
future.
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TABLE 8.1
Treatment Control
Total 
Male 
Female 
Average Age
44
17
27
63.4
48
32
16
58.9
TABLE 8.2 
Dukes Stage Treatment Control
35
9
31
17
TABLE 8.3
Treatment Control
Deaths
Recurrences
Dead due to recurrence 
Dead from, other causes
13
11
10
3
12
13
11
1
TABLE 8.4
Principal sites of recurrence Treatment Control
Local
Intr a-ahdominal 
Extra abdominal
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